

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Short-term exposure to pollen and the risk of allergic and asthmatic manifestations: A systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029069
Article Type:	Research
Date Submitted by the Author:	10-Jan-2019
Complete List of Authors:	Kitinoja, Milja; University of Oulu, Center for Environmental and Respiratory Health Research Hugg, Timo; University of Oulu, Center for Environmental and Respiratory Health Research Siddika, Nazeeba; University of Oulu, Center for Environmental and Respiratory Health Research Jaakkola, Maritta; University of Oulu, Center for Environmental and Respiratory Health Research Rodriguez Yanez, Daniel; University of Oulu, Center for Environmental and Respiratory Health Research Jaakkola, Jouni; University of Oulu, Center for Environmental and Respiratory Health Research
Keywords:	Epidemiology < TROPICAL MEDICINE, Public health < INFECTIOUS DISEASES, Allergy < THORACIC MEDICINE, Asthma < THORACIC MEDICINE

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

**Short-term exposure to pollen and the risk of allergic and asthmatic manifestations:
A systematic review and meta-analysis**

Milja A. Kitinoja, BM,^{1,2} Timo T. Hugg, PhD,^{1,2} Nazeeba Siddika, DSc, MSc,^{1,2} Daniel Rodriguez Yanez, BSc,^{1,2} Maritta S. Jaakkola, MD, PhD^{1,2}, Jouni J. K. Jaakkola, MD, PhD,^{1,2*}

¹ Center for Environmental and Respiratory Health Research, P.O.Box 5000 (Aapistie 5B), FIN-90014 University of Oulu, Oulu, Finland

² Medical Research Center Oulu, Oulu University Hospital and University of Oulu, P.O.Box 5000 (Aapistie 5A), FIN-90014 University of Oulu, Oulu, Finland

* Correspondence: Professor Jouni J.K. Jaakkola, Center for Environmental and Respiratory Health Research (CERH), University of Oulu, P.O. Box 5000 (Aapistie 5 B), 90014 Oulu, Finland; Tel.:+358406720927, E-mail address: jouni.jaakkola@oulu.fi.

Word count: text 3591, abstract 250

ABSTRACT

Background Several studies have assessed effects of short-term exposure to pollen on asthmatic and allergic manifestations. The evidence is inconclusive, and no meta-analysis has been published.

Objective To synthesize the evidence on the relations between short-term pollen exposure and the risk of allergic and asthmatic manifestations.

Methods We performed a systematic literature search of PubMed and Scopus databases up to the end of August 2018. In addition, we reviewed the reference lists of relevant articles. Two authors independently evaluated the eligible articles and extracted relevant information in a structured form. We calculated summary effect estimates (EE) based on the study-specific odds ratios and regression coefficients (β) by applying both fixed- and random-effects models.

Results 26 studies met the *a priori* eligibility criteria, and 12 of them provided sufficient information for the meta-analysis. The summary EE related to 10 grains per m³ increase in pollen exposure showed an 1% increase (EE=1.01 95% CI 1.00 to 1.02) in the risk of lower respiratory symptoms and a 2% increase (EE=1.02 95% CI 1.01 to 1.03) in the risk of any allergic or asthmatic symptom. Correspondingly, the risk of upper respiratory symptoms and ocular symptoms increased 7% (EE=1.07 95% CI 1.04 to 1.09) and 11% (EE= 1.11 95% CI 1.05 to 1.17), respectively, in relation to such pollen exposure. Short-term exposure to pollen did not show any significant effect on daily lung function levels.

Conclusion: Our results provide new evidence that short-term pollen exposure significantly increases the risks of allergic and asthmatic symptoms.

Strengths and limitations of this study

- Identification of individual studies based on a clearly defined and extensive (including secondary references) search strategy based on a priori set inclusion and exclusion criteria.
- The study-specific effect estimates were converted into comparable common effect estimates for exposure corresponding to 10 pollen grains increase per cubic meter.
- Publication bias was assessed by visual inspection of the funnel plots and application of Begg's and Egger's tests.
- For the first time, it is shown quantitatively using meta-analytic approach that short-term exposure to pollen grains increases the risks of allergic and/or asthmatic symptoms.
- The number of studies available for the sub-analyses investigating various outcomes was quite low.

Keywords

Allergy; asthma; panel study; pollen exposure; systematic review; meta-analysis

INTRODUCTION

Allergy and asthma are common diseases and consequently, of public health importance globally. Approximately 500 million people suffer from allergic rhinitis worldwide and more than 300 million people have asthma.[1-3] The prevalence of rhinitis and/or rhinoconjunctivitis varies globally between 1% and 45%[4] and that of asthma between 1% and 21%.[5] In Western Europe, the prevalence of allergic rhinitis and/or rhinoconjunctivitis ranges from 17% to 29%[6] and the prevalence of asthma from 6% to 18%.[7] Respectively, the prevalence of rhinitis and/or rhinoconjunctivitis and asthma are 12–30%[8] and 5-10% in the U.S.[9]

The majority of individuals suffering from allergic rhinitis experience seasonal symptoms when exposed to pollen.[10] Correspondingly, exposure to pollen grains increases the risk of asthma exacerbations among asthmatic persons.[11] Clinically meaningful threshold levels for pollen exposure have varied between 30 and 60 pollen grains per cubic meter of air.[12,13] However, exposures to relatively low levels of pollen (6-9 grains/m³) have been associated with asthma symptoms among those who already have this disease.[14] Pollen allergy has been found in 80–90% of children suffering from asthma and in 40–50% of adult-onset asthmatics.[15]

Several panel studies have suggested an association between short-term exposure to pollen and asthmatic/allergic manifestations, although the magnitude and statistical significance of such estimated relations have varied.[16-20] Lung function levels have not been found to clearly associate with pollen exposure.[21-25] However, the amount of exhaled nitric oxide (NO)[21,26] and asthma and/or allergy medication use[17,23] seem to increase during pollen season. Caillaud et al.[27] reviewed qualitatively three panel studies that provided some evidence on a relation between daily counts of atmospheric pollen and occurrence of health outcomes.

The panel studies on pollen exposure and manifestations of asthma or allergy have provided somewhat conflicting results.[22,28] To our knowledge there are no previous systematic reviews with meta-analysis that have assessed the effects of short-term pollen exposure on the risk of allergic and asthmatic symptoms and lung function. Therefore, we conducted a systematic review and meta-analysis to summarize the existing evidence on the relations between short-term exposure to pollen and the occurrence of various asthmatic and allergic symptoms and/or lung function manifestations.

METHODS

This systematic review and meta-analysis is based on a review protocol accessible online (<http://www.oulu.fi/cerh/node/50459>).

Search strategy and eligibility criteria

We performed a systematic literature search of PubMed and Scopus databases up to the end of August 2018, as shown in figure 1. In the first phase, we used the search terms “panel study” and “pollen”. In order to have a more extensive data search, we included the terms “pollen exposure”, “asthma”, “cohort study”, “longitudinal study”, “follow-up study”, “case-control study” and “cross-sectional study” in the second search.

Studies that met the following *a priori* eligibility criteria were included in this systematic review: the study (1) was an original study; (2) was a panel study where a group of people were followed longitudinally over a certain time period; (3) included asthmatic or allergic symptoms or measurements of lung function as the outcome; (4) included a study population of children or adults or both; and (5) reported on relations between daily mean airborne pollen exposure and manifestations of asthma and/or allergies.

Articles that were obviously irrelevant were excluded applying title screening. Articles that did not meet our *a priori* inclusion criteria were excluded by reading the abstract or full text. Reference lists of the articles that fulfilled the eligibility criteria were also reviewed and additional 14 articles fulfilling the criteria were included. Seven duplicate studies were excluded. The final number of the articles included in the systematic review was 26; 12 studies of them were included in the quantitative meta-analyses (see figure 1). Table 1 displays the characteristics of the 26 eligible studies.[13,14,16,18-20,22-26,28,45-58]

Table 1 Characteristics of the eligible studies included in the systematic review and meta-analysis (n = 26).

Reference (Region, country)	Study population	Study size (number of participants)	Follow-up (length and rate, %)	Outcomes	Method for pollen exposure assessment	NOS quality score ^a
Caillaud et al., 2012 ⁴⁵ (France and Switzerland)	Adults with hay fever sensitized to grass pollen	106	17 weeks; 71.1%	Self-reported ocular, nasal and lower respiratory symptoms	Regional monitoring by a volumetric pollen trap	4/9
Caillaud et al., 2014a ¹⁶ (France and Switzerland)	Adults with seasonal rhinitis sensitized to ragweed pollen	16 in 2009, 22 in 2010, a total of 30	11 weeks; 96.8%	Self-reported daily SAR symptoms: ocular (itching and/or tear flow and/or conjunctival redness), nasal (sneezing and/or runny nose and/or blocked nose) and respiratory (cough and/or wheezing and/or asthma) symptoms, use of medication	Regional monitoring by a volumetric pollen trap located 15 meters above the ground level	6/9
Caillaud et al., 2014c ⁴⁶ (France and Switzerland)	Adults with seasonal rhinitis sensitized to birch pollen	61	8 weeks; 85.9%	Self-reported daily SAR symptoms: ocular (itching and/or tear flow and/or conjunctival redness), nasal (sneezing and/or runny nose and/or blocked nose) and respiratory (cough and/or wheezing and/or asthma) symptoms	Regional monitoring by a volumetric pollen trap located 15 meters above the ground level	5/9
Delfino et al., 1996 ⁴⁹ (US)	9-18 years old subjects with physician-diagnosed asthma	12	6 weeks; 80.0%	Asthma symptoms (wheeze, cough, sputum production, shortness of breath, chest tightness) and use of as-needed beta-agonist inhalers	Regional monitoring by a volumetric pollen trap located 10 meters above the ground level	4/9
Delfino et al., 1997 ²² (US)	9-46 years old subjects with physician-diagnosed asthma sensitized to tree, grass or weed pollen	22	8 weeks; 91.7%	Self-reported daily asthma symptoms (cough, wheeze, sputum production, shortness of breath, and chest tightness), each evening and morning three PEF blows and daily asthma medication use (i.e. beta-agonist inhaler)	Regional monitoring by a volumetric pollen trap located 4 meters above the ground level	5/9

Delfino et al., 2002 ¹⁹ (US)	9-19 years old subjects with physician-diagnosed asthma	22	8 weeks; 88.0%	Self-reported daily asthma symptoms (cough, wheeze, sputum production, shortness of breath, and chest tightness)	Regional monitoring by a volumetric pollen trap located 4 meters above the ground level	5/9
DellaValle et al., 2012 ¹⁴ (US)	4-12 years old children with physician-diagnosed asthma	430	24-26 weeks during the years 2000-2004; 92.3%	Self-reported daily asthma symptoms (wheeze, night symptoms, shortness of breath, chest tightness, and persistent cough), use of asthma medication	Personal pollen exposure assessment based on modeling	5/9
Djukanović et al., 1996 ⁵⁰ (United Kingdom)	20-49 years old adults with atopic asthma	17	15 weeks; 94.1%	Self-reported asthma symptoms (nocturnal wheeze, nocturnal cough, morning chest tightness, day-time wheeze, subjective worsening of asthma due to exercise, cold air or fumes), self-reported morning and evening PEF values, FEV1	Not specified	1/9
Dominguez-Vilches et al., 1995 ⁵¹ (Spain)	Patients with pollen induced allergic rhinitis	70 in 1991 and 23 in 1992	12 weeks in 1991 and 12 weeks in 1992; 70.0% in 1991 and 46.0% in 1992	Daily conjunctival, nasal and respiratory symptoms	Regional monitoring by a volumetric pollen trap placed on the roof of a university building	2/9
Feo Brito et al., 2007 ⁴⁷ (Spain)	Subjects with mild to moderate seasonal asthma sensitized to grass and/or olive pollen	137	6 weeks; 90.1%	Self-reported symptoms of asthma, self-reported morning and evening PEF values	Regional monitoring by a volumetric pollen trap	4/9
Feo Brito et al., 2010 ¹³ (Spain)	10-51 years old patients with seasonal rhinitis and/or asthma, mono-sensitized to grass pollen	27	52 weeks; 100%	Self-reported symptoms / symptom and medication scores (including nasal obstruction, runny nose, sneezing/congestion, itching of the eyes, asthma attacks, use of medication)	Regional monitoring by a volumetric pollen trap located 15 meters above the ground level	2/9
Feo Brito et al., 2011 ⁴⁸ (Spain)	10-51 years old patients with seasonal rhinitis or asthma mono-sensitized to olive pollen	20	52 weeks; 100%	Self-reported symptoms (including conjunctival, nasal and respiratory symptoms)	Regional monitoring by a volumetric pollen trap located 15 meters above the ground level	3/9

Grammer et al., 1990 ⁵² (US)	Patients with history of ragweed rhinitis	29	10 weeks; 100%	Self-reported daily symptoms / symptom medication scores (nasal congestion, nasal discharge, sneezing, ocular pruritus, cough, use of medication)	Not specified; A rotating arm impactor and weekly pollen data were used	2/9
Jantunen et al., 2012 ⁵³ (Finland)	8-70 years old persons with physician-diagnosed birch pollen allergy (rhinoconjunctivitis)	28 in 2009 and 33 in 2010	8 weeks; 95.3%	Self-reported symptoms (conjunctival symptoms [itchy, swollen, watery, or sore eyes], nasal symptoms [sneezing, runny, itchy, or blocked nose], other allergy symptoms), use of medication	Regional pollen monitoring by a volumetric pollen trap located 14 meters above the ground level	3/9
Klabuschnigg et al., 1981 ⁵⁴ (Austria)	7-14 years old children with clinically-diagnosed asthma	40	6 weeks; 92.5%	Self-reported asthma symptoms, lung function (PEF, FEV1, FVC) measured every second day, use of medication	Regional pollen monitoring by a volumetric pollen trap located 12 meters above the ground level	2/9
Krämer et al., 2005 ⁵⁵ (Germany)	9 years old children with diagnosed allergic eczema	39	26 weeks; 69.6%	Self-reported daily eczema symptoms: itching and the extent of skin lesions	Regional pollen monitoring by a volumetric pollen trap located 12 meters above the ground level	5/9
Newhouse & Levetin, 2004 ²⁸ (US)	9-64 years old patients with physician-diagnosed asthma	24	8 weeks; 63.2%	Self-reported asthma symptoms, morning and evening PEF values	Regional pollen monitoring by a volumetric pollen trap located on the roof of a university building	3/9
Ostro et al., 2001 ²⁰ (US)	8-13 years old children with physician-diagnosed asthma	138	13 weeks; 90.2%	Self-reported daily asthma symptoms (shortness of breath, cough, and wheeze)	Pollen monitoring by a Rotod device (taking a sample for 30 seconds every 10 minutes)	5/9
Petersen & Sandberg, 1981 ⁵⁶ (Denmark)	Patients suffering from diagnosed pollen allergy	78	36 weeks; 83.2%	Daily scoring of symptoms and use of medication; before, during and after pollen season	Regional pollen data	3/9
Roberts et al., 2004 ²⁶ (United Kingdom)	7-16 years old children with mild to moderate seasonal allergic asthma and rhinoconjunctivitis sensitized to grass pollen	44	10 weeks; 100%	Exhaled NO –measurements and FEV1	Regional pollen monitoring by a volumetric pollen trap	4/9
Roberts et al., 2005 ¹⁸	6-17 years old children with seasonal allergic	84	12 weeks; 100%	Self-reported weekly pediatric allergic disease quality based on life	Regional pollen monitoring by a volumetric pollen trap	3/9

(United Kingdom)	rhinoconjunctivitis, asthma and/or eczema sensitized to grass pollen			questionnaire, symptoms (chest, nasal, ocular, cutaneous and other symptoms) and emotional problems		
Ross et al., 2002 ²³ (US)	5-49 years old subjects with asthma	40	26 weeks; 67.8%	Self-reported morning and evening PEF, symptom score, occurrence of asthma attacks and frequencies of asthma medication use	Local pollen monitoring by Rotorod devices located 2 meters above the ground level	4/9
Scarlett et al., 1996 ²⁴ (United Kingdom)	7-11 years old children with and without asthma	154	6 weeks; 100%	Daily lung function measurements (FEV0.75, FVC, FEV0.75/FVC)	Regional pollen monitoring, pollen counts were derived from the local monitoring site	6/9
Schäppi et al., 1998 ⁵⁷ (Australia)	17-50 years old volunteers with moderate to severe hay fever sensitized to grass pollen	21	3 weeks; 75.0%	Nasal (blockage, discharge or itching) and eye symptom scores (itching, swelling or running)	Regional pollen monitoring by a volumetric pollen trap located 14 meters above the ground level	3/9
Studnicka et al., 1995 ²⁵ (Austria)	7 years old and older children with and without asthma	47 in panel 1, 45 in panel 2, 41 in panel 3	3 weeks; 88.7%	Daily lung function measurements (FEV1, FVC, PEF)	Regional pollen monitoring by a volumetric pollen trap located 10 meters above the ground level	7/9
Taudorf & Moseholm, 1988 ⁵⁸ (Denmark)	16-47 years old pollinotic (hay fever) patients sensitized to birch pollen	15	16 weeks in 1983 and 16 weeks in 1984; 75.0%	Nose and eye symptom scores, use of medication	Regional pollen monitoring by a volumetric pollen trap	3/9

SAR, Seasonal allergic rhinitis. PEF, Peak expiratory flow. FEV1, Forced expiratory volume in the first second. FVC, Forced vital capacity. NO, Nitric oxide. FEV0.75, Forced expiratory volume at 3/4 of a second. ^a For panel studies, the maximum score is 7/9.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Outcome and exposure definitions

The outcome of interest was occurrence of asthma and/or allergy manifestations. The definitions of asthma and allergy manifestations included self- or parent-reported symptoms (lower and upper respiratory tract symptoms, ocular symptoms, skin symptoms and/or symptom scores), lung function measurements (Peak expiratory flow, PEF, Forced expiratory volume, FEV, Forced vital capacity, FVC, Exhaled nitric oxide, NO), and use of asthma and/or allergy medications. The exposure of interest was exposure to pollen, expressed as the amount of pollen grains per cubic meter of air sampled (grains/m³). The eligible definition of exposure included exposure to mean daily total airborne pollen or exposure to mean daily airborne pollen of distinct types (including birch, grass, ragweed, mugwort, olive, elm and/or hazel/alder pollen).

Data extraction and quality assessment

Eligible studies were examined and their relevant characteristics recorded in a standardized data extraction form independently by two authors (M.A.K. and D.R.Y.). Any disagreements were discussed together with additional two authors (T.T.H. and J.J.K.J.) until a consensus was achieved. Table 1 displays the main characteristics of the eligible studies. The study quality was assessed applying the Newcastle-Ottawa Scale (NOS) with the maximum score of 9.

In one study, the occurrence of asthmatic and allergic symptoms in relation to pollen exposure was investigated by recruiting a group of study subjects in two consecutive years.[16] There was some overlap among the study subjects, so that seven individuals (23% of participants) were included in both of these study groups. These two groups provided independent effect estimates (EE) for our meta-analysis. In another study, subjects were recruited in three distinct but successive periods of time within the pollen season.[25] These three groups also provided three independent effect estimates for the meta-analyses. The protocol was conducted according to PRISMA guidelines.[29]

Statistical methods

In the meta-analysis, we calculated summary effect estimates (EEs) from the study-specific odds ratios (OR) or regression coefficients (β) by using fixed- and random-effects models. When available, we preferred the adjusted EEs to the crude estimates. The summary EE from the fixed-effects model is presented when the study-specific EEs were homogenous, whereas the summary EE from the random-effects model is presented when moderate or substantial heterogeneity was

1
2
3 observed between the study-specific estimates. Heterogeneity was evaluated using the Q- and I²-
4 statistics. I²-statistic >50% indicates high, 25-50% moderate and <25% low heterogeneity.

5
6 Publication bias was assessed by visual inspection of the funnel plots and application of Begg's and
7 Egger's tests.[30,31] Individual studies included in the meta-analysis assessed their EEs in relation
8 to different levels of pollen exposure. Because of this, individual EEs were converted into a
9 common pollen concentration, i.e. as 10 pollen grains increase per cubic meter of air, before
10 estimating the summary effect.
11
12
13
14
15

16 Because of only a small number of studies or inadequacy of data in the existing studies, we were
17 not able to analyze potential relations between pollen exposure and skin symptoms, forced vital
18 capacity (FVC), exhaled NO or asthma and/or allergy medications. The panel studies with
19 asthmatic and/or allergic populations examined usually asthma- and allergy-related symptoms as
20 outcomes. In panel studies including general populations, the outcomes were lung function
21 measurements. We used the "metan" command of the Stata 11 statistical program to analyze the
22 fixed and random effects (StataCorp, College Station, Tex).
23
24
25
26
27
28
29

30 **Patient and public Involvement**

31 Due to nature of systematic review and meta-analysis, there was no patient and public
32 involvement in this study.
33
34
35
36
37

38 **RESULTS**

39 **Literature search**

40 A step-by-step approach of the literature search is presented in figure 1. Twenty-six studies met
41 the *a priori* inclusion criteria and were included in the systematic review, while 12 studies were
42 included in the meta-analysis. Ten of the 26 studies specifically investigated the relation between
43 total pollen exposure and asthmatic and/or allergic manifestations. Thirteen reported on grass
44 (*Poaceae*), 5 on birch (*Betula*), 5 on ragweed (*Ambrosia*), 3 on hazel/alder (*Corylus/Alnus*), 3 on
45 olive (*Olea*), 2 on elm (*Ulmus*), and 1 on mugwort (*Artemisia*) exposure and asthma and/or allergy
46 manifestations.
47
48
49
50
51
52
53
54
55

56 **Characteristics of included studies**

57 Characteristics of the 26 eligible studies are shown in table 1. In 13 studies subjects were
58 asthmatics, in 11 studies subjects were sensitized to pollen (i.e. positive Skin prick test, SPT or
59
60

1
2
3 Allergen-Specific Immunoglobulin E Test, IgE test) and in 8 studies subjects had hay fever (i.e.
4 allergic rhinitis, pollen allergy, pollinosis). One study investigated subjects with eczema. In 2
5 studies, subjects with and without asthma were analyzed together without taking into account the
6 prior disease status. Ten studies investigated children, four adults, and 9 both children and adults.
7 In 3 studies, authors did not specify the age of the subjects. Six studies applied logistic regression,
8 9 studies linear regression, 2 studies Poisson regression, and 2 studies time series regression for
9 the analyses.
10

11
12 The studies defined the outcomes in different ways. Sensitization based on SPT or IgE analysis
13 was the most common criterion used for the definition of allergy. Current presence of asthma,
14 previous history of asthmatic symptoms, and/or physician (i.e. clinical) diagnosis were also
15 frequently included as an outcome in the studies. We systematically categorized outcomes into
16 any symptom, lower respiratory tract symptoms, upper respiratory tract symptoms, ocular
17 symptoms, skin symptoms, symptom scores, lung function measurements (PEF, FEV, FVC and
18 exhaled NO), and use of asthma and/or allergy medications.
19

20
21 Pollen monitoring used for exposure assessment was based on regional sampling in 21 studies,
22 on local sampling in 2 studies, and on personal exposure modelling in one study. In 2 studies,
23 authors did not specify the type of pollen sampling. The height of the pollen sampler varied
24 between 2-15 meters above the ground level. Thirteen of the studies did not give the height
25 information for pollen sampler. Twenty-five studies expressed the mean pollen concentration as
26 pollen grains per cubic meter of air per 24 h. In 3 studies, daily pollen counts were converted into
27 weekly pollen sums, and consequently, the relations between weekly pollen counts and weekly
28 symptoms were presented. In 2 studies, hourly/bihourly pollen counts were presented in addition
29 to daily counts. Main outcomes for the studies that were not included into the meta-analysis are
30 presented in table 2.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2 The main findings in articles not included into the meta-analysis (n = 14)

Reference	Main findings
Delfino et al. 1996 ⁴⁹	Pollen exposure was not associated with either asthma symptom scores or as-needed beta-agonist inhaler use.
Delfino et al. 1997 ²²	Pollen exposure was not associated with asthma symptom severity, morning or evening peak expiratory flow rate (PEFR), or β -agonist inhaler use.
Djukanovic et al. 1996 ⁵⁰	The peak pollen season was associated with a significant increase in asthma symptoms.
Dominguez-Vilches et al. 1995 ⁵¹	A greater seasonal pollen intensity was associated with a higher occurrence of daily symptoms.
Feo Brito et al. 2010 ¹³	A significant positive association was found between the presence of symptoms and pollen grains.
Grammer et al. 1990 ⁵²	The peak pollen periods were associated with a twofold increase in symptom-medication scores among a subset of patients.
Jantunen et al. 2012 ⁵³	The number of subjects with allergy symptoms increased significantly with the daily pollen concentrations.
Klabuschnigg et al. 1981 ⁵⁴	Two hourly pollen counts or daily pollen counts were not associated with the frequency of asthma attacks. In contrast, consecutive 10-day mean symptom scores (assessing asthma attacks) associated with the total pollen counts. No associations were found between pollen exposure and lung function measurement (including PEF, FEV1 and FVC).
Krämer et al. 2005 ⁵⁵	Pollen exposure had no significant effect on skin symptom severity among children with winter type eczema. In contrast, grass-pollen exposure showed a significant effect on the severity of skin symptoms among children with summer type eczema.
Newhouse & Levetin 2004 ²⁸	<i>Ambrosia</i> pollen concentrations were significantly correlated with composite asthma scores, rhinitis scores and several individual symptoms. <i>Chenopodiaceae/Amaranthaceae</i> pollen concentrations showed significant associations with composite asthma scores. <i>Ulmus</i> , <i>Chenopodiaceae/Amaranthaceae</i> and <i>Poaceae</i> pollen concentrations showed significant correlations with composite rhinitis scores. Pollen concentrations significantly influenced morning (but not evening) PEF values measured in the following day.
Petersen & Sandberg 1981 ⁵⁶	There was a positive association between the appearance of pollen grains in the air and the symptom-medication score.
Roberts et al. 2004 ²⁶	Fractional exhaled nitric oxide (FENO) levels increased significantly during the grass pollen season. There were no apparent associations between pollen counts and other lung function measurements.
Schäppi et al. 1998 ⁵⁷	The grass pollen counts associated significantly with the average nasal and eye symptom scores
Taudorf & Moseholm 1988 ⁵⁸	Occurrence of symptoms and daily medication increased during the season with a constant pollen load.

PEFR, Peak expiratory flow rate = PEF, Peak expiratory flow. FEV1, Forced expiratory volume in the first second. FVC, Forced vital capacity. FENO, Fractional exhaled nitric oxide.

Relations between pollen exposure and asthma- and allergy-related symptoms among allergic / asthmatic subjects

The summary EE for the relation between pollen exposure and any symptoms was statistically significantly increased at 1.02 (95% confidence interval (CI): 1.01-1.03) from the random effects model (figures 2, 3 and Supplementary File, figure 1). The study-specific estimates showed high heterogeneity. This estimate was based on 6 studies (providing 9 EEs). The funnel plot and the results from the Begg's ($z = -1.25$; P value = 0.211) and Egger's tests (Bias coefficient .0457453; 95% CI -.0048418-.0963324; P value = 0.070) on short-term pollen exposure and any symptoms provided no indication of publication bias (Supplementary File, figure 2).

A total of 6 studies (9 EEs) provided study-specific EEs for pollen exposure and lower respiratory symptoms. The summary EE from the random effects model was 1.01 (95% CI: 1.00-1.02). The study-specific estimates showed high heterogeneity.

The summary EE for pollen exposure and upper respiratory symptoms, based on 3 studies (4 EEs), was significantly increased at 1.07 (95% CI: 1.04-1.09) from the random effects model. There was moderate heterogeneity between the study-specific estimates.

The relation between pollen exposure and ocular symptoms was reported in 3 studies (4 EEs). The summary EE from the random-effects model was 1.11 (95% CI: 1.05-1.17). The study-specific estimates showed high heterogeneity.

The relation between pollen exposure and symptom scores was based on 4 studies applying linear regression modelling (giving regression coefficients). The summary EE was significantly elevated (1.003; 95% CI: 1.001-1.004). The study-specific estimates showed high heterogeneity.

Relations between pollen exposure and lung function among general population

The relation between pollen exposure and peak expiratory flow (PEF) was assessed in 2 studies (giving 4 EEs), resulting in a summary EE of 0.98 for 10 pollen grains increase per cubic meter of air (95% CI: 0.95-1.01) in the random effects model based on linear regression modelling. The study-specific estimates showed large heterogeneity.

Two studies estimated the relation between pollen exposure and forced expiratory volume (FEV). One study used forced expiratory volume in the first second, FEV1 as the outcome and the other forced expiratory volume at 3/4 of a second, FEV0.75. Different FEV estimates were combined in the analysis. Meta-analysis gave the summary EE of 1.00 for 10 pollen grains increase

per cubic meter of air (95% CI: 0.99-1.01) in the fixed effects model based on linear regression modelling. There was little heterogeneity between the studies.

Relations between pollen exposure and use of asthma and/or allergy medication

In 2 studies, the use of asthma and/or allergy medication was combined with information on asthma and/or allergy symptoms (in forming symptom-medication score). In 5 studies that investigated the relation between pollen exposure and the use of medication, pollen exposure increased the use of medication. In contrast, 3 studies did not show any association between pollen exposure and use of allergy/asthma medication.

DISCUSSION

Main findings

This systematic review and meta-analysis provides new evidence that short-term pollen exposure significantly increases the risk of asthmatic and allergic symptoms. The summary EE for a 10 grains /m³ increase in pollen exposure showed on average a 2% increase in the risk of any asthmatic or allergic symptom. The corresponding increases in the risk of upper respiratory symptoms and ocular symptoms were 7% and 11%, respectively. All summary EEs were statistically significant. This meta-analysis did not show any statistically significant relations between pollen exposure and lung function measurements. The summary EE for 10 grains /m³ increase in pollen exposure indicated a 2% decrease in PEF values, while no change was detected in relation to FEV values.

Risk of bias across the studies

In the majority of studies, exposure assessment was based on single stationary regional sampler located on the roof level (table 1). Although it has been suggested that different types of pollen sampling can be used to get a rough estimate of pollen exposure,[32] many of the approaches may not capture in satisfactory detail daily individual exposures at the breathing level. In 2013, we monitored grass pollen concentrations at 16 sites in the cities of Helsinki and Espoo during the peak pollen season by using rotorod-type samplers at the breathing height.[33] We identified substantial variation in exposure concentrations at breathing height according to urbanity of the site and time of the day within areas covered by our roof level monitoring stations. Most valid estimates of pollen exposure could be obtained by using personal pollen sampling. There were also other potential sources of heterogeneity in the exposure measured by these studies linked to

1
2
3 variation in weather/climatic conditions, period of monitoring, nature of pollen season, daily
4 activities/time spent outdoors by the study subjects, and pollen types monitored.

5
6
7 In all studies, selection of study subjects was based on predefined and justified eligibility criteria.
8
9 Due to the study design including inference based on within-individual variation of health
10
11 outcome, the risk of selection bias is rather small. Also the relatively high follow-up rates (varying
12
13 from 46.0 to 100%) across studies reduce the risk of selection bias. However, there was substantial
14
15 diversity in the type and measurement of outcomes, which resulted in difficulties in forming the
16
17 major outcome groups for the meta-analyses. Status of asthma and/or allergic diseases varied
18
19 from mild to moderate or from moderate to severe.

20
21 The studies could be divided roughly into two major groups on the basis of what kind of
22
23 adjustment was applied for confounding. The first group of studies provided only descriptive
24
25 results without any or only with very basic statistical analyses. The second group performed
26
27 extensive statistical analyses, including controlling for a few or several confounders. Due to study
28
29 design where individuals act as their own controls on days with no (major) exposure, individual
30
31 characteristics are not potential confounders. In contrast, environmental factors, such as
32
33 temperature and air pollution can be potential confounders. A significant number of the studies
34
35 adjusted for temperature (13) and other meteorological parameters (12), as well as for air
36
37 pollution (4). Other potential sources of heterogeneity include variation in the studied time lags
38
39 between the exposure and the outcome (varying from 0 to 14 days), potential differences in
40
41 allergen content of pollen of interest, and different characteristics and size of the study
42
43 populations (varying from 12 to 430 subjects). In 24 studies, the study focused on asthmatics
44
45 and/or subjects with allergies, whereas two studies included both healthy and non-healthy
46
47 subjects.[24,25]

47 **Validity of results**

48
49 The strengths of our study include identification of individual studies based on a clearly defined
50
51 search strategy. In addition to the primary PubMed and Scopus database searches, we also used
52
53 secondary references that were cited by the articles and reviews identified in the primary search
54
55 to achieve as complete set of studies as possible. Two reviewers checked independently the
56
57 eligibility of the studies according to *a priori* set inclusion and exclusion criteria and identified the
58
59 most appropriate effect estimate.
60

1
2
3 The present systematic review and meta-analysis focused on panel studies mainly with relatively
4 brief follow-up periods. The follow-up periods in the studies varied from 3 weeks to 52 weeks.
5
6 However, pollen related asthmatic and allergic symptoms are usually induced after only a few
7 hours or days of exposure.[34,35] Thus, variable and/or relatively short follow-up periods are
8 probably not problematic when assessing the relationship between pollen exposure and outcomes
9 of interest in this study.
10
11
12
13

14 Our statistical analyses included 12 studies, because only 12 studies out of a total of 26
15 presented the exact mean or interquartile range (IQR) values of pollen grains per cubic meter.
16 Information on the mean and IQR values were needed to convert the study-specific effect
17 estimates into common effect estimates for exposure corresponding to 10 pollen grains increase
18 per cubic meter. The aim of this transformation was to make studies containing different pollen
19 concentration values comparable. Although the total number of panel studies was reasonable, the
20 numbers of studies available for the sub-analyses investigating various outcomes were quite low.
21 Therefore, the conclusions based on results of the sub-analyses should be interpreted with
22 caution.
23
24
25
26
27
28
29

30 “Any exposure” was applied in the analyses due to the heterogeneity of exposure assessment.
31 Total daily mean pollen concentration values were preferred, but when such were not available,
32 information on the mean daily airborne concentration of distinct pollen types (birch, grass,
33 ragweed, mugwort, olive, elm and/or hazel/alder) was used as the measure of exposure in the
34 analyses. This should not cause any problem, because the pollen seasons of different pollen types
35 commonly overlap, so individuals can react to exposure to several pollen types. Consequently, the
36 reaction to pollen exposure is likely to be a combined reaction to a sum of various pollen
37 types.[36] It is not always possible to define exactly which specific pollen type caused the
38 symptoms. Therefore, the exact separation of distinct pollen types in health effect studies is
39 somewhat artificial and thus, unnecessary.
40
41
42
43
44
45
46
47
48
49
50

51 **Synthesis with previous knowledge**

52 Our results indicated that short-term pollen exposure increases the risk of any respiratory or other
53 allergic symptom, lower and upper respiratory symptoms and ocular symptoms among asthmatic
54 and/or allergic subjects. In a recent systematic review and meta-analysis of 14 studies,[37] the
55 mean number of emergency department attendance among children and adolescents with asthma
56 increased 1.88% (95% CI = 0.94%-2.82%) in relation to a 10 grass pollen grain increase per cubic
57
58
59
60

meter. These results are in line with a recent ecologic study from Japan, where a positive association was observed between cedar and cypress pollen counts and the prevalence of symptoms of allergic rhinoconjunctivitis and asthma in school children.[38] Similarly, our results are also in line with the register-based time-series analysis among Belgian population, where a positive association was observed between pollen exposure and allergy medication sales.[39] A time-stratified case-crossover study showed a positive association between tree and weed pollen exposure and emergency department visits due to asthma exacerbations among 13-17 year-old U.S. asthmatics.[40]

According to our results, the effect of pollen exposure was stronger in upper respiratory tract than in lower respiratory tract. This could be explained by the large size of the pollen grain. Generally, the size of pollen varies between 20 and 100 micrometers in diameter.[41] Therefore, particles of pollen grain size do not penetrate well into the lower respiratory tract.[42] Pollen grains are likely to adhere and release their allergenic content already in the upper respiratory tract. As a consequence of this, the majority of the direct allergic inflammatory effects caused by pollen may be experienced in the region of the upper respiratory tract.

Our systematic review did not detect any major effect of pollen exposure on lung function. The results may be explained by the fact that the study population for lung function effects included healthy people in addition to asthmatic and allergic subjects. If these studies would only include asthmatic and/or allergic persons, more pronounced effects might be detected. In the Swedish cohort-based study, exposure to grass pollen during the preceding day was associated with a reduced forced expiratory volume in relation to an increase in three pollen counts ($/m^3$) among the 8-year-old children.[43] This association was more pronounced among children who were sensitized to pollen allergens. In line with those results, another study of Swedish adults showed that pollen exposure resulted in significantly increased concentration of nitric oxide in exhaled air, which suggested increased airway inflammation among these asthmatics compared to the healthy controls.[44]

Conclusions

This systematic review and meta-analysis provides new evidence that short-term exposure to pollen grains increases any respiratory symptoms, as well as specifically upper respiratory and ocular symptoms among asthmatic and allergic subjects. It is important that clinicians take into account, when working with allergic and asthma patients that even relatively short-term exposure

1
2
3 to pollen can induce for them symptoms of allergies and asthma. Clinicians should advice allergic
4 and asthmatic subjects to avoid spending much time outdoors during the (main) pollen periods,
5 and to use adequate allergy and asthma medications when such exposures cannot be avoided.
6
7 Future studies should use personal exposure assessment and it would be important to find out
8 how the variation in pollen exposure affects the health of allergic and asthmatic subjects.
9
10
11
12
13

14 **Acknowledgments**

15
16 We thank Riitta Aittamaa for her valuable assistance with figure editing. We also thank the
17 organizing committee of the 6th European Symposium on Aerobiology held in Lyon, France, July
18 2016 to possibility to present the main results of the study.
19
20
21
22

23 **Contributors**

24
25 JJ and TH conceived the study; MK, DRY and TH reviewed the articles, NS and MK analyzed the
26 data under supervision of JJ; MK, TH, MJ, and JJ wrote the manuscript, all authors contributed to
27 the intellectual content and approved the final version
28
29
30
31

32 **Data sharing statement**

33
34 No additional data available.
35
36
37

38 **Patient consent**

39
40 Not required
41
42
43

44 **Funding**

45
46 This work was supported by the Research Council for Health, the Academy of Finland [grant
47 numbers 266314, 267675, 267995 (APTA Consortium) and 24302585 (GLORIA Consortium)], and
48 the University of Oulu Strategic Funding. The funders had no role in study design, data collection
49 or analysis, decision to publish, or preparation of the manuscript.
50
51
52
53

54
55 **Competing Interests** None declared.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends to the figures

Figure 1 Flow diagram showing searches and study selection.

Figure 2 Forest plot for the relation between pollen exposure and any symptom (Weights are from random effects analysis).

Figure 3 A Forest plot for the relation between pollen exposure and lower respiratory symptoms (Weights are from random effects analysis). **B.** Forest plot for the relation between pollen exposure and upper respiratory symptoms. **C.** Forest plot for the relation between pollen exposure and ocular symptoms (Weights are from random effects analysis). **D.** Forest plot for the relation between pollen exposure and symptom score (Weights are from random effects analysis).

Supplementary File, Figure 1 A. Forest plot for the relation between pollen exposure and peak expiratory flow (PEF; Weights are from random effects analysis). **B.** Forest plot for the relation between pollen exposure and forced expiratory volume (FEV).

Supplementary File, Figure 2 Funnel plot with pseudo 95% confidence limits for the relation between short-term pollen exposure and any symptom.

REFERENCES

1. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. *Allergy*2004;59:469–478.
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). *Allergy*2008;86:8–160.
3. Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. *Ther Adv Respir Dis*2012;6:11–23.
4. Ait-Khaled N, Pearce N, Anderson HR, et al. ISAAC Phase Three Study Group. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. *Allergy*2009;64:123–148.
5. Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to asthma control. *Eur Respir J*2015;46:622–639.
6. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. *Eur Respir J*2004;24:758–764.
7. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. *BMC Public Health*2012;12:204.
8. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. *Allergy Asthma Proc*2008;29:600–608.
9. National Health Interview Survey (NHIS) Data; Most Recent Asthma Data. The Centers for Disease Control and Prevention (CDC), 2016. https://www.cdc.gov/asthma/most_recent_data.htm (accessed 25 September 2018).
10. Blomme K, Tomassen P, Lapeere H, et al. Prevalence of allergic sensitization versus allergic rhinitis symptoms in an unselected population. *Int Arch Allergy Immunol*2013;160:200–207.
11. Darrow LA, Hess J, Rogers CA, et al. Ambient pollen concentrations and emergency department visits for asthma and wheeze. *J Allergy Clin Immunol*2012;130(3):630–638.
12. Annesi-Maesano I, Rouve S, Desqueyroux H, et al. Grass pollen counts, air pollution levels and allergic rhinitis severity. *Int Arch Allergy Immunol*2012;158:397–404.
13. Feo Brito F, Mur Gimeno P, Carnés J, et al. Grass pollen, aeroallergens, and clinical symptoms in Ciudad Real, Spain. *J Investig Allergol Clin Immunol*2010;20(4):295–302.
14. DellaValle CT, Triche EW, Leaderer BP, et al. Effects of Ambient Pollen Concentrations on Frequency and Severity of Asthma Symptoms among Asthmatic Children. *Epidemiology*2012;23(1):55–63.
15. Taylor PE, Jacobson KW, House JM, et al. Links between pollen, atopy and the asthma epidemic. *Int Arch Allergy Immunol*2007;144:162–170.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


16. Caillaud D, Thibaudon M, Martin S, et al. Short-term effects of airborne ragweed pollen on clinical symptoms of hay fever in a panel of 30 patients. *J Investig Allergol Clin Immunol*2014a;24(4):249–256.
17. Häfner D, Reich K, Matricardi PM, et al. Prospective validation of ‘Allergy-Control-SCORE™’: a novel symptom–medication score for clinical trials. *Allergy*2011;66:629–636.
18. Roberts G, Mylonopoulou M, Hurley C, et al. Impairment in quality of life is directly related to the level of allergen exposure and allergic airway inflammation. *Clin Exp Allergy*2005;35:1295–1300.
19. Delfino RJ, Zeiger RS, Seltzer JM, et al. Association of asthma symptoms with peak particulate air pollution and effect modification by anti-inflammatory medication use. *Environ Health Perspect*2002;110(10):A607–A617.
20. Ostro B, Lipsett M, Mann J, et al. Air pollution and exacerbation of asthma in African-American children in Los Angeles. *Epidemiology*2001;12:200–208.
21. Baraldi E, Carrà S, Dario C, et al. Effect of natural grass pollen exposure on exhaled nitric oxide in asthmatic children. *Am J Respir Crit Care Med*1999;159:262–266.
22. Delfino RJ, Zeiger RS, Seltzer JM, et al. The effect of outdoor fungal spore concentrations on daily asthma severity. *Environ Health Perspect*1997;105(6):622–635.
23. Ross MA, Persky VW, Scheff PA, et al. Effect of ozone and aeroallergens on the respiratory health of asthmatics. *Arch Environ Health*2002;57(6):568–578.
24. Scarlett JF, Abbott KJ, Peacock JL, et al. Acute effects of summer air pollution on respiratory function in primary school children in southern England. *Thorax*1996;51:1109–1114.
25. Studnicka MJ, Frischer T, Meinert R, et al. Acidic particles and lung function in children: a summer camp study in the Austrian Alps. *Am J Respir Crit Care Med*1995;151:423–430.
26. Roberts G, Hurley C, Bush A, et al. Longitudinal study of grass pollen exposure, symptoms, and exhaled nitric oxide in childhood seasonal allergic asthma. *Thorax*2004;59:752–756.
27. Caillaud D, Toloba Y, Raobison R, et al. Health impact of exposure to pollens: A review of epidemiological studies. [Article in French]. *Rev Mal Respir*2014b;31(2):142–149.
28. Newhouse CP, Levetin E. Correlation of environmental factors with asthma and rhinitis symptoms in Tulsa OK. *Ann Allergy Asthma Immunol*2004;92:356–366.
29. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. 2009. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med*6(7):e1000097.
30. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*1994;50(4):1088–1101.
31. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ*1997;315(7109):629–634.

- 1
2
3 32. Riediker M, Keller S, Wüthrich B, et al. Personal pollen exposure compared to stationary
4 measurements. *J Investig Allergol Clin Immunol*2000;10(4):200–203.
5
6 33. Hugg TT, Hjort J, Antikainen H, et al. Urbanity as a determinant of exposure to grass pollen in
7 Helsinki Metropolitan area, Finland. *PLOS ONE*2017;12(10):e0186348.
8
9 34. Osborne NJ, Alcock I, Wheeler BW, et al. Pollen exposure and hospitalization due to asthma
10 exacerbations: daily time series in a European city. *Int J Biometeorol*2017;61(10):1837–1848.
11
12 35. Robertson DG, Kerigan AT, Hargreave FE, et al. Late asthmatic responses induced by ragweed
13 pollen allergen. *J Allergy Clin Immunol*1974;54(4):244–254.
14
15 36. D'Amato G, Cecchi L, Bonini S, et al. Allergenic pollen and pollen allergy in Europe.
16 *Allergy*2007;62(9):976–990.
17
18 37. Erbas B, Jazayeri M, Lambert KA, et al. Outdoor pollen is a trigger of child and adolescent
19 asthma emergency department presentations: A systematic review and meta-analysis.
20 *Allergy*2018;73(8):1632–1641.
21
22 38. Yoshida K, Adachi Y, Akashi M, et al. Cedar and cypress pollen counts are associated with the
23 prevalence of allergic diseases in Japanese schoolchildren. *Allergy*2013;68(6):757–763.
24
25 39. Guilbert A, Simons K, Hoebeke L, et al. Short-term effect of pollen and spore exposure on
26 allergy morbidity in the Brussels-Capital region. *Ecohealth*2016; 13(2):303–315.
27
28 40. Gleason JA, Bielory L, Fagliano JA. Associations between ozone, PM2.5, and four pollen types
29 on emergency department pediatric asthma events during the warm season in New Jersey: a case-
30 crossover study. *Environ Res*2014;132:421–429.
31
32 41. Haahtela T, Sorsa P. Kasviallergiat ja allergiakasvit [Plant allergies and allergenic plants; in
33 Finnish]. Helsinki: Kirjayhtymä 1999.
34
35 42. Suphioglu C, Singh MB, Taylor P, et al. Mechanism of grass-pollen-induced asthma.
36 *Lancet*1992;339(8793):569–572.
37
38 43. Gruzieva O, Pershagen G, Wickman M, et al. Exposure to grass pollen--but not birch pollen--
39 affects lung function in Swedish children. *Allergy*2015;70(9):1181–1183.
40
41 44. Bake B, Viklund E, Olin AC. Effects of pollen season on central and peripheral nitric oxide
42 production in subjects with pollen asthma. *Respir Med*2014;108(9):1277–1283.
43
44 45. Caillaud DM, Martin S, Segala C, et al. Nonlinear short-term effects of airborne Poaceae levels
45 on hay fever symptoms. *J Allergy Clin Immunol*2012;130(3):812–814.
46
47 46. Caillaud D, Martin S, Segala C, et al. Effects of airborne birch pollen levels on clinical symptoms
48 of seasonal allergic rhinoconjunctivitis. *Int Arch Allergy Immunol*2014c;163:43–50.
49
50 47. Feo Brito F, Mur Gimeno P, Martínez C, et al. Air pollution and seasonal asthma during the
51 pollen season. A cohort study in Puertollano and Ciudad Real (Spain). *Allergy*2007;62(10):1152–
52 1157.
53
54
55
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

48. Feo Brito F, Mur Gimeno P, Carnés J, et al. *Olea europaea* pollen counts and aeroallergen levels predict clinical symptoms in patients allergic to olive pollen. *Ann Allergy Asthma Immunol*2011;106(2):146–152.
49. Delfino RJ, Coate BD, Zeiger RS, et al. Daily asthma severity in relation to personal ozone exposure and outdoor fungal spores. *Am J Respir Crit Care Med*1996;154:633–641.
50. Djukanović R, Feather I, Gratziau C, et al. Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. *Thorax*1996;51(6):575–581.
51. Domínguez-Vilches E, Cariñanos P, Galán Soldevilla C, et al. Airborne pollen concentrations, solid particle content in the air and allergy symptoms in Córdoba (Spain). *Aerobiologia*1995;11(2):129–135.
52. Grammer L, Wiggins C, Shaughnessy MA, et al. Absence of nasal priming as measured by rhinitis symptom scores of ragweed allergic patients during seasonal exposure to ragweed pollen. *Allergy Proc*1990;11(5):243–246.
53. Jantunen J, Saarinen K, Rantio-Lehtimäki A. Allergy symptoms in relation to alder and birch pollen concentrations in Finland. *Aerobiologia*2012;28:169–176.
54. Klabuschnigg A, Götz M, Horak F, et al. Influence of aerobiology and weather on symptoms in children with asthma. *Respiration*1981;42(1):52–60.
55. Krämer U, Weidinger S, Darsow U, et al. Seasonality in symptom severity influenced by temperature or grass pollen: results of a panel study in children with eczema. *J Invest Dermatol*2005;124:514–523.
56. Petersen BN, Sandberg I. Diagnostics in allergic diseases by correlating pollen/fungal spore counts with patient scores of symptoms. *Grana*1981;20:219–224.
57. Schäppi GF, Taylor PE, Kenrick J, et al. Predicting the grass pollen count from meteorological data with regard to estimating the severity of hayfever symptoms in Melbourne (Australia). *Aerobiologia*1998;14:29–37.
58. Taudorf E, Moseholm L. Pollen count, symptom and medicine score in birch pollinosis. A mathematical approach. *Int Arch Allergy Appl Immunol*1988;86:225–233.







A Lower respiratory symptoms




B Upper respiratory symptoms






C Ocular symptoms



D Symptom score









PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	2
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	4
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	9, FIG1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	9
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	study protocol
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	14
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	9



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	14
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	N/A
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICCO, follow-up period) and provide the citations.	Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Table 1
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	FIG2-FIG3, Suppl Fig1
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	FIG2-FIG3, Suppl Fig1
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	14
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	14-16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16-17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	18



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only

136/bmjopen-2019-029029 on 10 January 2020. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

BMJ Open

Short-term exposure to pollen and the risk of allergic and asthmatic manifestations: A systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029069.R1
Article Type:	Original research
Date Submitted by the Author:	01-Aug-2019
Complete List of Authors:	Kitinoja, Milja; University of Oulu, Center for Environmental and Respiratory Health Research Hugg, Timo; University of Oulu, Center for Environmental and Respiratory Health Research Siddika, Nazeeba; University of Oulu, Center for Environmental and Respiratory Health Research Jaakkola, Maritta; University of Oulu, Center for Environmental and Respiratory Health Research Rodriguez Yanez, Daniel; University of Oulu, Center for Environmental and Respiratory Health Research Jaakkola, Jouni; University of Oulu, Center for Environmental and Respiratory Health Research
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Respiratory medicine, Public health
Keywords:	Epidemiology < TROPICAL MEDICINE, Public health < INFECTIOUS DISEASES, Allergy < THORACIC MEDICINE, Asthma < THORACIC MEDICINE

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Short-term exposure to pollen and the risk of allergic and asthmatic manifestations:**
2 **A systematic review and meta-analysis**

3 Milja A. Kitinoja, BM,^{1,2} Timo T. Hugg, PhD,^{1,2} Nazeeba Siddika, DSc, MSc,^{1,2} Daniel Rodriguez
4 Yanez, BSc,^{1,2} Maritta S. Jaakkola, MD, PhD^{1,2}, Jouni J. K. Jaakkola, MD, PhD,^{1,2*}

5 ¹ Center for Environmental and Respiratory Health Research, P.O.Box 5000 (Aapistie 5B), FIN-
6 90014 University of Oulu, Oulu, Finland

7 ² Medical Research Center Oulu, Oulu University Hospital and University of Oulu, P.O.Box 5000
8 (Aapistie 5A), FIN-90014 University of Oulu, Oulu, Finland

9 * Correspondence: Professor Jouni J.K. Jaakkola, Center for Environmental and Respiratory Health
10 Research (CERH), University of Oulu, P.O. Box 5000 (Aapistie 5 B), 90014 Oulu, Finland;
11 Tel.:+358406720927, E-mail address: jouni.jaakkola@oulu.fi.

14 **Word count: text 3744, abstract 249**

32 ABSTRACT

33 **Background** Several studies have assessed effects of short-term exposure to pollen on asthmatic and
34 allergic manifestations. The evidence is inconclusive, and no meta-analysis has been published.

35 **Objective** To synthesize the evidence on the relations between short-term pollen exposure and the risk of
36 allergic and asthmatic manifestations.

37 **Methods** We performed a systematic literature search of PubMed and Scopus databases up to the end of
38 August 2018. In addition, we reviewed the reference lists of relevant articles. Two authors independently
39 evaluated the eligible articles and extracted relevant information in a structured form. We calculated
40 summary effect estimates (EE) based on the study-specific odds ratios and regression coefficients (β) by
41 applying both fixed- and random-effects models.

42 **Results** 26 studies met the *a priori* eligibility criteria, and 12 of them provided sufficient information for the
43 meta-analysis. The summary EE related to 10 grains per m³ increase in pollen exposure showed an 1%
44 increase (EE=1.01 95% CI 1.00 to 1.02) in the risk of lower respiratory symptoms and a 2% increase (EE=1.02
45 95% CI 1.01 to 1.03) in the risk of any allergic or asthmatic symptom. Correspondingly, the risk of upper
46 respiratory symptoms and ocular symptoms increased 7% (EE=1.07 95% CI 1.04 to 1.09) and 11% (EE= 1.11
47 95% CI 1.05 to 1.17), respectively, in relation to such pollen exposure. Short-term exposure to pollen did
48 not show any significant effect on daily lung function levels.

49 **Conclusion:** Our results provide new evidence that short-term pollen exposure significantly increases the
50 risks of allergic and asthmatic symptoms.

52 **Strengths and limitations of this study**

- 53 • Identification of individual studies based on a clearly defined and extensive search strategy based on a
54 priori set inclusion and exclusion criteria.
- 55 • Also, secondary references were included
- 56 • The study-specific effect estimates were converted into comparable effect estimates for exposure
57 corresponding to 10 pollen grains increase per cubic meter.
- 58 • Publication bias was assessed by visual inspection of the funnel plots and by applying Begg's and Egger's
59 tests.
- 60 • The number of studies available for the sub-analyses investigating effects on various outcomes was quite
61 low.

63 **Keywords**

64 Allergy; asthma; panel study; pollen exposure; systematic review; meta-analysis

66 INTRODUCTION

67 Allergy and asthma are common diseases and consequently, of public health importance globally.
68 Approximately 500 million people suffer from allergic rhinitis worldwide and more than 300
69 million people have asthma.[1-3] The prevalence of rhinitis and/or rhinoconjunctivitis varies
70 globally between 1% and 45%[4] and that of asthma between 1% and 21%.[5] In Western Europe,
71 the prevalence of allergic rhinitis and/or rhinoconjunctivitis ranges from 17% to 29%[6] and the
72 prevalence of asthma from 6% to 18%.[7] Respectively, the prevalence of rhinitis and/or
73 rhinoconjunctivitis and asthma are 12–30%[8] and 5-10% in the U.S.[9]

74 The prevalence of physician-diagnosed pollen-induced allergic rhinitis was 18.5% among people
75 living in northern China.[10] The majority of individuals suffering from allergic rhinitis experience
76 seasonal symptoms when exposed to pollen.[11] Correspondingly, exposure to pollen grains
77 increases the risk of asthma exacerbations among asthmatic persons.[12] There are no universally
78 accepted, clinically meaningful threshold levels for pollen exposure. In previous studies, threshold
79 levels have varied between 30 and 60 pollen grains per cubic meter of air.[13,14] However,
80 exposures to relatively low levels of pollen (6-9 grains/m³) have been associated with asthma
81 symptoms among those who already have this disease.[15] Pollen allergy has been found in 80–
82 90% of children suffering from asthma and in 40–50% of adult-onset asthmatics.[16]

83 Several panel studies have suggested an association between short-term exposure to pollen and
84 asthmatic/allergic manifestations, although the magnitude and statistical significance of such
85 estimated relations have varied.[17-21] Lung function levels have not been found to clearly
86 associate with pollen exposure.[22-26] However, the amount of exhaled nitric oxide (NO)[22,27]
87 and asthma and/or allergy medication use[18,24] seem to increase during pollen season. Caillaud
88 et al.[28] reviewed qualitatively three panel studies that provided some evidence on a relation
89 between daily counts of atmospheric pollen and occurrence of health outcomes.

90 The panel studies on pollen exposure and manifestations of asthma or allergy have provided
91 somewhat conflicting results.[23,29] To our knowledge there are no previous systematic reviews
92 with meta-analysis that have assessed the effects of short-term pollen exposure on the risk of
93 allergic and asthmatic symptoms and lung function. Therefore, we conducted a systematic review
94 and meta-analysis to summarize the existing evidence on the relations between short-term
95 exposure to pollen and the occurrence of various asthmatic and allergic symptoms and/or lung
96 function manifestations.

METHODS

This systematic review and meta-analysis is based on a review protocol accessible online (<http://www.oulu.fi/cerh/node/50459>).

Search strategy and eligibility criteria

We performed a systematic literature search of PubMed and Scopus databases up to the end of August 2018, as shown in figure 1. In the first phase, we used the search terms “panel study” and “pollen”. In order to have a more extensive data search, we included the terms “pollen exposure”, “asthma”, “cohort study”, “longitudinal study”, “follow-up study”, “case-control study” and “cross-sectional study” in the second search. All languages were included in the search.

Studies that met the following *a priori* eligibility criteria were included in this systematic review: the study (1) was an original study; (2) was a panel study where a group of people were followed longitudinally over a certain time period; (3) included asthmatic or allergic symptoms or measurements of lung function as the outcome; (4) included a study population of children or adults or both; and (5) reported on relations between daily mean airborne pollen exposure and manifestations of asthma and/or allergies.

Articles that were obviously irrelevant were excluded applying title screening. Articles that did not meet our *a priori* inclusion criteria were excluded by reading the abstract or full text.

Outcome and exposure definitions

The outcome of interest was occurrence of asthma and/or allergy manifestations. The definitions of asthma and allergy manifestations included self- or parent-reported symptoms (lower and upper respiratory tract symptoms, ocular symptoms, skin symptoms and/or symptom scores), lung function measurements (Peak expiratory flow, PEF, Forced expiratory volume, FEV, Forced vital capacity, FVC, Exhaled nitric oxide, NO), and use of asthma and/or allergy medications. The exposure of interest was exposure to pollen, expressed as the amount of pollen grains per cubic meter of air sampled (grains/m³). The eligible definition of exposure included exposure to mean daily total airborne pollen or exposure to mean daily airborne pollen of distinct types (including birch, grass, ragweed, mugwort, olive, elm and/or hazel/alder pollen). All the available studies assessed the associations between pollen concentrations and symptoms during the same day, i.e. the duration of short-term exposure was here one day.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

129 **Data extraction and quality assessment**

130 Eligible studies were examined and their relevant characteristics recorded in a standardized data
131 extraction form independently by two authors (M.A.K. and D.R.Y.). Any disagreements were
132 discussed together with additional two authors at the end of the data extraction process (T.T.H.
133 and J.J.K.J.) until a consensus was achieved. Table 1 displays the main characteristics of the eligible
134 studies. The study quality was assessed applying the Newcastle-Ottawa Scale (NOS) with the
135 maximum score of 9.

136 In one study, the occurrence of asthmatic and allergic symptoms in relation to pollen exposure
137 was investigated by recruiting a group of study subjects in two consecutive years.[17] There was
138 some overlap among the study subjects, so that seven individuals (23% of participants) were
139 included in both of these study groups. These two groups provided independent effect estimates
140 (EE) for our meta-analysis. In another study, subjects were recruited in three distinct but
141 successive periods of time within the pollen season.[26] These three groups also provided three
142 independent effect estimates for the meta-analyses. The protocol was conducted according to
143 PRISMA guidelines.[30]

145 **Statistical methods**

146 In the meta-analysis, we calculated summary effect estimates (EEs) from the study-specific odds
147 ratios (OR) or regression coefficients (β) by using fixed- and random-effects models. When
148 available, we preferred the adjusted EEs to the crude estimates. The summary EE from the fixed-
149 effects model is presented when the study-specific EEs were homogenous, whereas the summary
150 EE from the random-effects model is presented when moderate or substantial heterogeneity was
151 observed between the study-specific estimates. Heterogeneity was evaluated using the Q- and I²-
152 statistics. I²-statistic >50% indicates high, 25-50% moderate and <25% low heterogeneity.
153 Publication bias was assessed by visual inspection of the funnel plots and application of Begg's and
154 Egger's tests.[31,32] Individual studies included in the meta-analysis assessed their EEs in relation
155 to different levels of pollen exposure. Because of this, individual EEs were converted into a
156 common pollen concentration, i.e. as 10 pollen grains increase per cubic meter of air, before
157 estimating the summary effect.

158 Because of only a small number of studies or inadequacy of data in the existing studies, we were
159 not able to analyze potential relations between pollen exposure and skin symptoms, forced vital
160 capacity (FVC), exhaled NO or asthma and/or allergy medications. The panel studies with

1
2
3 161 asthmatic and/or allergic populations examined usually asthma- and allergy-related symptoms as
4
5 162 outcomes. In panel studies including general populations, the outcomes were lung function
6
7 163 measurements. We used the “metan” command of the Stata 11 statistical program to analyze the
8
9 164 fixed and random effects (StataCorp, College Station, Tex).

10 165 11 12 166 **Patient and public Involvement**

13
14 167 Due to nature of systematic review and meta-analysis, there was no patient and public
15
16 168 involvement in this study.

17 169 18 19 170 **RESULTS**

20 171 **Literature search**

21
22 172 Reference lists of the articles that fulfilled the eligibility criteria were also reviewed and additional
23
24 173 14 articles fulfilling the criteria were included. Seven duplicate studies were excluded. A step-by-
25
26 174 step approach of the literature search is presented in figure 1. Twenty-six studies met the *a priori*
27
28 175 inclusion criteria and were included in the systematic review, while 12 studies of them were
29
30 176 included in the quantitative meta-analysis. Table 1 displays the characteristics of the 26 eligible
31
32 177 studies.[14,15,17,19-21,23-27,29,33-46]

33
34 178 Ten of the 26 studies specifically investigated the relation between total pollen exposure and
35
36 179 asthmatic and/or allergic manifestations. Thirteen reported on grass (*Poaceae*), 5 on birch
37
38 180 (*Betula*), 5 on ragweed (*Ambrosia*), 3 on hazel/alder (*Corylus/Alnus*), 3 on olive (*Olea*), 2 on elm
39
40 181 (*Ulmus*), and 1 on mugwort (*Artemisia*) exposure and asthma and/or allergy manifestations.

185 **Table 1** Characteristics of the eligible studies included in the systematic review and meta-analysis (n = 26).

Reference (Region, country)	Study population	Study size (number of participants)	Follow-up (length and rate, %)	Outcomes	Method for pollen exposure assessment and the level of exposure expressed as mean daily pollen concentrations (pollen grains/m ³ of air)	NOS quality score ^a
Caillaud et al., 2012 ³³ (France and Switzerland)	Adults with hay fever sensitized to grass pollen	106	17 weeks; 71.1%	Self-reported ocular, nasal and lower respiratory symptoms	Regional monitoring by a volumetric pollen trap; range 0-133	4/9
Caillaud et al., 2014a ¹⁷ (France and Switzerland)	Adults with seasonal rhinitis sensitized to ragweed pollen	16 in 2009, 22 in 2010, a total of 30	11 weeks; 96.8%	Self-reported daily SAR symptoms: ocular (itching and/or tear flow and/or conjunctival redness), nasal (sneezing and/or runny nose and/or blocked nose) and respiratory (cough and/or wheezing and/or asthma) symptoms, use of medication	Regional monitoring by a volumetric pollen trap located 15 meters above the ground level; range 0-543	6/9
Caillaud et al., 2014c ³⁴ (France and Switzerland)	Adults with seasonal rhinitis sensitized to birch pollen	61	8 weeks; 85.9%	Self-reported daily SAR symptoms: ocular (itching and/or tear flow and/or conjunctival redness), nasal (sneezing and/or runny nose and/or blocked nose) and respiratory (cough and/or wheezing and/or asthma) symptoms	Regional monitoring by a volumetric pollen trap located 15 meters above the ground level; range 0-400-	5/9
Delfino et al., 1996 ³⁵ (US)	9-18 years old subjects with physician-diagnosed asthma	12	6 weeks; 80.0%	Asthma symptoms (wheeze, cough, sputum production, shortness of breath, chest tightness) and use of as-needed beta-agonist inhalers	Regional monitoring by a volumetric pollen trap located 10 meters above the ground level; range 4-115	4/9
Delfino et al., 1997 ²³ (US)	9-46 years old subjects with physician-diagnosed asthma sensitized to tree, grass or weed pollen	22	8 weeks; 91.7%	Self-reported daily asthma symptoms (cough, wheeze, sputum production, shortness of breath, and chest tightness), each evening and morning three PEF blows and daily asthma medication use (i.e. beta-agonist inhaler)	Regional monitoring by a volumetric pollen trap located 4 meters above the ground level; range 11-611	5/9

Delfino et al., 2002 ²⁰ (US)	9-19 years old subjects with physician-diagnosed asthma	22	8 weeks; 88.0%	Self-reported daily asthma symptoms (cough, wheeze, sputum production, shortness of breath, and chest tightness)	Regional monitoring by a volumetric pollen trap located 4 meters above the ground level; range 12-1257	5/9
DellaValle et al., 2012 ¹⁵ (US)	4-12 years old children with physician-diagnosed asthma	430	24-26 weeks during the years 2000-2004; 92.3%	Self-reported daily asthma symptoms (wheeze, night symptoms, shortness of breath, chest tightness, and persistent cough), use of asthma medication	Personal pollen exposure assessment based on modeling; range 0-4187	5/9
Djukanović et al., 1996 ³⁶ (United Kingdom)	20-49 years old adults with atopic asthma	17	15 weeks; 94.1%	Self-reported asthma symptoms (nocturnal wheeze, nocturnal cough, morning chest tightness, day-time wheeze, subjective worsening of asthma due to exercise, cold air or fumes), self-reported morning and evening PEF values, FEV1	Not specified; range 0-318 (based on weekly pollen counts)	1/9
Dominguez-Vilches et al., 1995 ³⁷ (Spain)	Patients with pollen induced allergic rhinitis	70 in 1991 and 23 in 1992	12 weeks in 1991 and 12 weeks in 1992; 70.0% in 1991 and 46.0% in 1992	Daily conjunctival, nasal and respiratory symptoms	Regional monitoring by a volumetric pollen trap placed on the roof of a university building; ranges of pollen concentrations are not clearly stated	2/9
Feo Brito et al., 2007 ³⁸ (Spain)	Subjects with mild to moderate seasonal asthma sensitized to grass and/or olive pollen	137	6 weeks; 90.1%	Self-reported symptoms of asthma, self-reported morning and evening PEF values	Regional monitoring by a volumetric pollen trap; ranges 1-550 (grasses) and 0-596 (olive)	4/9
Feo Brito et al., 2010 ¹⁴ (Spain)	10-51 years old patients with seasonal rhinitis and/or asthma, mono-sensitized to grass pollen	27	52 weeks; 100%	Self-reported symptoms / symptom and medication scores (including nasal obstruction, runny nose, sneezing/congestion, itching of the eyes, asthma attacks, use of medication)	Regional monitoring by a volumetric pollen trap located 5 meters above the ground level; range 0-585	2/9
Feo Brito et al., 2011 ³⁹ (Spain)	10-51 years old patients with seasonal rhinitis or asthma mono-sensitized to olive pollen	20	52 weeks; 100%	Self-reported symptoms (including conjunctival, nasal and respiratory symptoms)	Regional monitoring by a volumetric pollen trap located 15 meters above the ground level; range 0-443	3/9

Grammer et al., 1990 ⁴⁰ (US)	Patients with history of ragweed rhinitis	29	10 weeks; 100%	Self-reported daily symptoms / symptom medication scores (nasal congestion, nasal discharge, sneezing, ocular pruritus, cough, use of medication)	Not specified; A rotating arm impactor and weekly pollen data were used; range 0-2100	2/9
Jantunen et al., 2012 ⁴¹ (Finland)	8-70 years old persons with physician-diagnosed birch pollen allergy (rhinoconjunctivitis)	28 in 2009 and 33 in 2010	8 weeks; 95.3%	Self-reported symptoms (conjunctival symptoms [itchy, swollen, watery, or sore eyes], nasal symptoms [sneezing, runny, itchy, or blocked nose], other allergy symptoms), use of medication	Regional pollen monitoring by a volumetric pollen trap located 14 meters above the ground level; ranges 0-1970 (alders) and 0-6890 (birches)	3/9
Klabuschnigg et al., 1981 ⁴² (Austria)	7-14 years old children with clinically-diagnosed asthma	40	6 weeks; 92.5%	Self-reported asthma symptoms, lung function (PEF, FEV1, FVC) measured every second day, use of medication	Regional pollen monitoring by a volumetric pollen trap located 12 meters above the ground level; ranges of pollen concentrations are not clearly stated	2/9
Krämer et al., 2005 ⁴³ (Germany)	9 years old children with diagnosed allergic eczema	39	26 weeks; 69.6%	Self-reported daily eczema symptoms: itching and the extent of skin lesions	Regional pollen monitoring by a volumetric pollen trap located 12 meters above the ground level; ranges 0-215 (haze/alder), 0-1673 (birches), 0-184 (grasses) and 0-10 (mugworts)	5/9
Newhouse & Levetin, 2004 ²⁹ (US)	9-64 years old patients with physician-diagnosed asthma	24	8 weeks; 63.2%	Self-reported asthma symptoms, morning and evening PEF values	Regional pollen monitoring by a volumetric pollen trap located on the roof of a university building; ranges 1-498 (ragweeds), 0-167 (elms), 0-13 (grasses)	3/9
Ostro et al., 2001 ²¹ (US)	8-13 years old children with physician-diagnosed asthma	138	13 weeks; 90.2%	Self-reported daily asthma symptoms (shortness of breath, cough, and wheeze)	Pollen monitoring by a Rotod device (taking a sample for 30 seconds every 10 minutes); range 1-75	5/9
Petersen & Sandberg, 1981 ⁴⁴ (Denmark)	Patients suffering from diagnosed pollen allergy	78	36 weeks; 83.2%	Daily scoring of symptoms and use of medication; before, during and after pollen season	Regional pollen data; range 0-1600 (based on weekly pollen counts)	3/9

Roberts et al., 2004 ²⁷ (United Kingdom)	7-16 years old children with mild to moderate seasonal allergic asthma and rhinoconjunctivitis sensitized to grass pollen	44	10 weeks; 100%	Exhaled NO –measurements and FEV1	Regional pollen monitoring by a volumetric pollen trap; range 0-178	4/9
Roberts et al., 2005 ¹⁹ (United Kingdom)	6-17 years old children with seasonal allergic rhinoconjunctivitis, asthma and/or eczema sensitized to grass pollen	84	12 weeks; 100%	Self-reported weekly pediatric allergic disease quality based on life questionnaire, symptoms (chest, nasal, ocular, cutaneous and other symptoms) and emotional problems	Regional pollen monitoring by a volumetric pollen trap; ranges of pollen concentrations are not clearly stated	3/9
Ross et al., 2002 ²⁴ (US)	5-49 years old subjects with asthma	40	26 weeks; 67.8%	Self-reported morning and evening PEF, symptom score, occurrence of asthma attacks and frequencies of asthma medication use	Local pollen monitoring by Rotohod devices located 2 meters above the ground level; range 0-1492	4/9
Scarlett et al., 1996 ²⁵ (United Kingdom)	7-11 years old children with and without asthma	154	6 weeks; 100%	Daily lung function measurements (FEV0.75, FVC, FEV0.75/FVC)	Regional pollen monitoring, pollen counts were derived from the local monitoring site; range 2-183	6/9
Schäppi et al., 1998 ⁴⁵ (Australia)	17-50 years old volunteers with moderate to severe hay fever sensitized to grass pollen	21	3 weeks; 75.0%	Nasal (blockage, discharge or itching) and eye symptom scores (itching, swelling or running)	Regional pollen monitoring by a volumetric pollen trap located 14 meters above the ground level; range 0-400	3/9
Studnicka et al., 1995 ²⁶ (Austria)	7 years old and older children with and without asthma	47 in panel 1, 45 in panel 2, 41 in panel 3	3 weeks; 88.7%	Daily lung function measurements (FEV1, FVC, PEF)	Regional pollen monitoring by a volumetric pollen trap located 10 meters above the ground level; ranges of pollen concentrations are not clearly stated	7/9
Taudorf & Moseholm, 1988 ⁴⁶ (Denmark)	16-47 years old pollinotic (hay fever) patients sensitized to birch pollen	15	16 weeks in 1983 and 16 weeks in 1984; 75.0%	Nose and eye symptom scores, use of medication	Regional pollen monitoring by a volumetric pollen trap; ranges of pollen concentrations are not clearly stated	3/9

186 SAR, Seasonal allergic rhinitis. PEF, Peak expiratory flow. FEV1, Forced expiratory volume in the first second. FVC, Forced vital capacity. NO, Nitric oxide.
 187 FEV0.75, Forced expiratory volume at 3/4 of a second. ^a For panel studies, the maximum score is 7/9.

188

bmjopen-2019-02-0669 on 10 June 2019
 Downloaded from <http://bmjopen.bmj.com/>
 by guest on 13 April 2019

1
2**3 189 Characteristics of included studies**

4
5 190 Characteristics of the 26 eligible studies are shown in table 1. In 13 studies subjects were
6
7 191 asthmatics, in 11 studies subjects were sensitized to pollen (i.e. positive Skin prick test, SPT or
8
9 192 Allergen-Specific Immunoglobulin E Test, IgE test) and in 8 studies subjects had hay fever (i.e.
10
11 193 allergic rhinitis, pollen allergy, pollinosis). One study investigated subjects with eczema. In 2
12
13 194 studies, subjects with and without asthma were analyzed together without taking into account the
14
15 195 prior disease status. Ten studies investigated children, four adults, and 9 both children and adults.
16
17 196 In 3 studies, authors did not specify the age of the subjects. Six studies applied logistic regression,
18
19 197 9 studies linear regression, 2 studies Poisson regression, and 2 studies time series regression for
20
21 198 the analyses.

22 199 The studies defined the allergic and/or asthmatic manifestations in different ways. Sensitization
23
24 200 based on SPT or IgE analysis was the most common criterion used for the definition of allergy.
25
26 201 Current presence of asthma, previous history of asthmatic symptoms, and/or physician (i.e.
27
28 202 clinical) diagnosis were frequently applied as inclusion criteria in the reviewed studies. We
29
30 203 systematically categorized outcomes into any symptom, lower respiratory tract symptoms, upper
31
32 204 respiratory tract symptoms, ocular symptoms, skin symptoms, symptom scores, lung function
33
34 205 measurements (PEF, FEV, FVC and exhaled NO), and use of asthma and/or allergy medications.

35 206 Pollen monitoring used for exposure assessment was based on regional sampling in 21 studies,
36
37 207 on local sampling in 2 studies, and on personal exposure modelling in one study. In 2 studies,
38
39 208 authors did not specify the type of pollen sampling. The height of the pollen sampler varied
40
41 209 between 2-15 meters above the ground level. Thirteen of the studies did not give the height
42
43 210 information for pollen sampler. Twenty-five studies expressed the mean pollen concentration as
44
45 211 pollen grains per cubic meter of air per 24 h. In 3 studies, daily pollen counts were converted into
46
47 212 weekly pollen sums, and consequently, the relations between weekly pollen counts and weekly
48
49 213 symptoms were presented. In 2 studies, hourly/bihourly pollen counts were presented in addition
50
51 214 to daily counts. Main outcomes for the studies that were not included into the meta-analysis are
52
53 215 presented in table 2.

54 216

55 217 Risk of bias across the studies

56 218 In the majority of studies, exposure assessment was based on single stationary regional sampler
57
58 219 located on the roof level (Table 1). Although it has been suggested that different types of pollen
59
60 220 sampling can be used to get a rough estimate of pollen exposure,[47] many of the approaches may

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

221 not have captured the daily individual exposures at the breathing level in satisfactory detail. In
222 2013, we monitored grass pollen concentrations at 16 sites in the cities of Helsinki and Espoo
223 during the peak pollen season by using rotorod-type samplers at the breathing height.[48] We
224 identified substantial variation in exposure concentrations at breathing height according to
225 urbanity of the site and time of the day within areas covered by our roof level monitoring stations.
226 Most valid estimates of pollen exposure could be obtained by using personal pollen sampling.
227 There were also other potential sources of heterogeneity in the exposure measured by these
228 studies linked to variation in weather/climatic conditions, type and period of monitoring, nature of
229 pollen season, daily activities/time spent outdoors by the study subjects, variation in the height of
230 monitoring and pollen types monitored.

231 In all studies, selection of study subjects was based on predefined and justified eligibility criteria.
232 Due to the study design that included inference based on within-individual variation of health
233 outcome, the risk of selection bias is rather small (Supplementary table 1). Also the relatively high
234 follow-up rates (varying from 46.0 to 100%) across studies reduce the risk of selection bias.
235 However, there was substantial diversity in the type and measurement of outcomes, which
236 resulted in difficulties in forming the major outcome groups for the meta-analyses. Status of
237 asthma and/or allergic diseases varied from mild to moderate or from moderate to severe.

238 The studies could be divided roughly into two major groups on the basis of what kind of
239 adjustment was applied for confounding. The first group of studies provided only descriptive
240 results without any or only with very basic statistical analyses. The second group performed
241 extensive statistical analyses, including controlling for a few or several confounders. Due to study
242 design where individuals act as their own controls on days with no (major) exposure, individual
243 characteristics were not potential confounders. In contrast, environmental factors, such as
244 temperature and air pollution can be potential confounders. A significant number of the studies
245 adjusted for temperature (13) and other meteorological parameters (12), as well as for air
246 pollution (4). Other potential sources of heterogeneity include variation in the studied time lags
247 between the exposure and the outcome (varying from 0 to 14 days), potential differences in
248 allergen content of pollen of interest, and different characteristics and size of the study
249 populations (varying from 12 to 430 subjects). In 24 studies, the study focused on asthmatics
250 and/or subjects with allergies, whereas two studies included both healthy and non-healthy
251 subjects.[25,26]

252 **Table 2** The main findings in articles not included into the meta-analysis (n = 14)

Reference	Main findings
Delfino et al. 1996 ³⁵	Pollen exposure was not associated with either asthma symptom scores or as-needed beta-agonist inhaler use.
Delfino et al. 1997 ²³	Pollen exposure was not associated with asthma symptom severity, morning or evening peak expiratory flow rate (PEFR), or β -agonist inhaler use.
Djukanovic et al. 1996 ³⁶	The peak pollen season was associated with a significant increase in asthma symptoms (P<0.05).
Dominguez-Vilches et al. 1995 ³⁷	A greater seasonal pollen intensity was associated with a higher occurrence of daily symptoms.
Feo Brito et al. 2010 ¹⁴	A significant positive association was found between the presence of symptoms and pollen grains (r=0.62; P<0.001).
Grammer et al. 1990 ⁴⁰	The peak pollen periods were associated with a twofold increase in symptom-medication scores among a subset of patients.
Jantunen et al. 2012 ⁴¹	The number of subjects with allergy symptoms increased significantly with the daily pollen concentrations (r = 0.35-0.36, P<0.01).
Klabuschnigg et al. 1981 ⁴²	Two hourly pollen counts or daily pollen counts were not associated with the frequency of asthma attacks. In contrast, consecutive 10-day mean symptom scores (assessing asthma attacks) associated with the total pollen counts. No associations were found between pollen exposure and lung function measurement (including PEF, FEV1 and FVC).
Krämer et al. 2005 ⁴³	Pollen exposure had no significant effect on skin symptom severity among children with winter type eczema (relative change in grass pollen exposure 0.98-1.00; 95% confidence limits 0.81-1.18). In contrast, grass-pollen exposure showed a significant effect on the severity of skin symptoms among children with summer type eczema (relative change in grass pollen exposure 1.16-1.19; 95% confidence limits 1.02-1.39).
Newhouse & Levetin 2004 ²⁹	<i>Ambrosia</i> pollen concentrations were significantly correlated with composite asthma scores (r=0.263, P<0.05), rhinitis scores (r=0.513, P<0.001) and several individual symptoms. <i>Chenopodiaceae/Amaranthaceae</i> pollen concentrations showed significant associations with composite asthma scores (r=0.256, P<0.05). <i>Urtica</i> (r=0.367, P<0.01), <i>Chenopodiaceae/Amaranthaceae</i> (r=0.458, P<0.001) and <i>Poaceae</i> (r=0.326, P<0.05) pollen concentrations showed significant correlations with composite rhinitis scores. Pollen concentrations significantly influenced morning (but not evening) PEF values measured in the following day (r=-0.261--0.364, P<0.05-0.01).
Petersen & Sandberg 1981 ⁴⁴	There was a positive association between the appearance of pollen grains in the air and the symptom-medication score.
Roberts et al. 2004 ²⁷	Fractional exhaled nitric oxide (FENO) levels increased significantly during the grass pollen season (median change 2.9 ppb, 95% confidence interval 1.5-5.4). There were no apparent associations between pollen counts and other lung function measurements.
Schäppi et al. 1998 ⁴⁵	The grass pollen counts associated significantly with the average nasal (r=0.637, P<0.001) and eye symptom (r=0.586, P<0.005) scores.
Taudorf & Moseholm 1988 ⁴⁶	Occurrence of symptoms and daily medication increased during the season with a constant pollen load.

1
2 253 PEFR, Peak expiratory flow rate = PEF, Peak expiratory flow. FEV1, Forced expiratory volume in the first second. FVC, Forced vital capacity. FENO, Fractional
3 254 exhaled nitric oxide.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

bmjopen-2019-029069 on 10 January 2020. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

1
2

3 255 **Relations between pollen exposure and asthma- and allergy-related symptoms among allergic /** 4 5 256 **asthmatic subjects**

6
7 257 A total of 12 studies were included in the meta-analyses. In 8 studies [15,17,20,21,33,34,38,39]
8
9 258 the effect estimate was based on odds ratio and in 4 studies [19, 24-26] on a regression coefficient
10
11 259 which was or was converted to a change per 10 grains per m³ of air. The summary EE for the
12
13 260 relation between pollen exposure and any symptoms was statistically significantly increased at
14
15 261 1.02 (95% confidence interval (CI): 1.01-1.03) from the random effects model (figures 2, 3 and
16
17 262 Supplementary File, figure 1). The study-specific estimates showed high heterogeneity. This
18
19 263 estimate was based on 6 studies (providing 9 EEs). The funnel plot and the results from the Begg's
20
21 264 (z= -1.25; P value= 0.211) and Egger's tests (Bias coefficient .0457453; 95% CI -.0048418-.0963324;
22
23 265 P value= 0.070) on short-term pollen exposure and any symptoms provided no indication of
24
25 266 publication bias (Supplementary File, figure 2).

26
27 267 A total of 6 studies (9 EEs) provided study-specific EEs for pollen exposure and lower respiratory
28
29 268 symptoms. The summary EE from the random effects model was 1.01 (95% CI: 1.00-1.02). The
30
31 269 study-specific estimates showed high heterogeneity.

32
33 270 The summary EE for pollen exposure and upper respiratory symptoms, based on 3 studies (4
34
35 271 EEs), was significantly increased at 1.07 (95% CI: 1.04-1.09) from the random effects model. There
36
37 272 was moderate heterogeneity between the study-specific estimates.

38
39 273 The relation between pollen exposure and ocular symptoms was reported in 3 studies (4 EEs).
40
41 274 The summary EE from the random-effects model was 1.11 (95% CI: 1.05-1.17). The study-specific
42
43 275 estimates showed high heterogeneity.

44
45 276 The relation between pollen exposure and symptom scores was based on 4 studies applying
46
47 277 linear regression modelling (giving regression coefficients). The summary EE was significantly
48
49 278 elevated (1.003; 95% CI: 1.001-1.004). The study-specific estimates showed high heterogeneity.

50 280 **Relations between pollen exposure and lung function among general population**

51
52 281 The relation between pollen exposure and peak expiratory flow (PEF) was assessed in 2 studies
53
54 282 (giving 4 EEs), resulting in a summary EE of 0.98 for 10 pollen grains increase per cubic meter of air
55
56 283 (95% CI: 0.95-1.01) in the random effects model based on linear regression modelling. The study-
57
58 284 specific estimates showed large heterogeneity.

59
60 285 Two studies estimated the relation between pollen exposure and forced expiratory volume
61
62 286 (FEV). One study used forced expiratory volume in the first second, FEV₁ as the outcome and the

1
2
3 287 other forced expiratory volume at 3/4 of a second, FEV_{0.75}. Different FEV estimates were
4
5 288 combined in the analysis. Meta-analysis gave the summary EE of 1.00 for 10 pollen grains increase
6
7 289 per cubic meter of air (95% CI: 0.99-1.01) in the fixed effects model based on linear regression
8
9 290 modelling. There was little heterogeneity between the studies.

10 291 11 12 292 **Relations between pollen exposure and use of asthma and/or allergy medication**

13
14 293 In 2 studies, the use of asthma and/or allergy medication was combined with information on
15
16 294 asthma and/or allergy symptoms (in forming symptom-medication score). In 5 studies that
17
18 295 investigated the relation between pollen exposure and the use of medication, pollen exposure
19
20 296 increased the use of medication. In contrast, 3 studies did not show any association between
21
22 297 pollen exposure and use of allergy/asthma medication.

23 298 24 25 299 **DISCUSSION**

26 27 300 **Main findings**

28
29 301 This systematic review and meta-analysis provides new evidence that short-term pollen exposure
30
31 302 significantly increases the risk of asthmatic and allergic symptoms. The summary EE for a 10 grains
32
33 303 /m³ increase in pollen exposure showed on average a 2% increase in the risk of any asthmatic or
34
35 304 allergic symptom. The corresponding increases in the risk of upper respiratory symptoms and
36 305 ocular symptoms were 7% and 11%, respectively. All summary EEs were statistically significant.
37
38 306 This meta-analysis did not show any statistically significant relations between pollen exposure and
39
40 307 lung function measurements. The summary EE for 10 grains /m³ increase in pollen exposure
41
42 308 indicated a 2% decrease in PEF values, while no change was detected in relation to FEV values.

43 309 44 45 310 **Validity of results**

46
47 311 The strengths of our study include identification of individual studies based on a clearly defined
48
49 312 search strategy. In addition to the primary PubMed and Scopus database searches, we also used
50
51 313 secondary references that were cited by the articles and reviews identified in the primary search
52
53 314 to achieve as complete set of studies as possible. Two reviewers checked independently the
54
55 315 eligibility of the studies according to *a priori* set inclusion and exclusion criteria and identified the
56 316 most appropriate effect estimate.

57
58 317 The present systematic review and meta-analysis focused on panel studies mainly with relatively
59
60 318 brief follow-up periods. The follow-up periods in the studies varied from 3 weeks to 52 weeks.

1
2
3 319 However, pollen related asthmatic and allergic symptoms are usually induced after only a few
4
5 320 hours or days of exposure.[49,50] Thus, variable and/or relatively short follow-up periods are
6
7 321 probably not problematic when assessing the relationship between pollen exposure and outcomes
8
9 322 of interest in this study.

10
11 323 Our statistical analyses included 12 studies, because only 12 studies out of a total of 26
12
13 324 presented the exact mean or interquartile range (IQR) values of pollen grains per cubic meter.
14
15 325 Information on the mean and IQR values were needed to convert the study-specific effect
16
17 326 estimates into common effect estimates for exposure corresponding to 10 pollen grains increase
18
19 327 per cubic meter. The aim of this transformation was to make studies containing different pollen
20
21 328 concentration values comparable. Although the total number of panel studies was reasonable, the
22
23 329 numbers of studies available for the sub-analyses investigating various outcomes were quite low.
24
25 330 Therefore, the conclusions based on results of the sub-analyses should be interpreted with
26
27 331 caution.

28
29 332 "Any exposure" was applied in the analyses due to the heterogeneity of exposure assessment.
30
31 333 Total daily mean pollen concentration values were preferred, but when such were not available,
32
33 334 information on the mean daily airborne concentration of distinct pollen types (birch, grass,
34
35 335 ragweed, mugwort, olive, elm and/or hazel/alder) was used as the measure of exposure in the
36
37 336 analyses. This should not cause any problem, because the pollen seasons of different pollen types
38
39 337 commonly overlap, so individuals can react to exposure to several pollen types. Consequently, the
40
41 338 reaction to pollen exposure is likely to be a combined reaction to a sum of various pollen
42
43 339 types.[51] It is not always possible to define exactly which specific pollen type caused the
44
45 340 symptoms. Therefore, the exact separation of distinct pollen types in health effect studies is
46
47 341 somewhat artificial and thus, unnecessary.

48 342

49 343 **Synthesis with previous knowledge**

50
51 344 Our results indicated that short-term pollen exposure increases the risk of any respiratory or other
52
53 345 allergic symptom, lower and upper respiratory symptoms and ocular symptoms among asthmatic
54
55 346 and/or allergic subjects. Depending on the plant species, concentrations of pollen grains in the
56
57 347 breathing air can vary between zero and thousands. Eventually, increases in pollen exposure can
58
59 348 have a considerable effect on the well-being of allergic/asthmatic people. In a recent systematic
60
61 349 review and meta-analysis of 14 studies,[52] the mean number of emergency department
62
63 350 attendance among children and adolescents with asthma increased 1.88% (95% CI = 0.94%-2.82%)

1
2
3 351 in relation to a 10 grass pollen grain increase per cubic meter. These results are in line with a
4
5 352 recent ecologic study from Japan, where a positive association was observed between cedar and
6
7 353 cypress pollen counts and the prevalence of symptoms of allergic rhinoconjunctivitis and asthma
8
9 354 in school children.[53] Similarly, our results are also in line with the register-based time-series
10
11 355 analysis among Belgian population, where a positive association was observed between pollen
12
13 356 exposure and allergy medication sales.[54] A time-stratified case-crossover study showed a
14
15 357 positive association between tree and weed pollen exposure and emergency department visits
16
17 358 due to asthma exacerbations among 13-17 year- old U.S. asthmatics.[55]

18 359 According to our results, the effect of pollen exposure was stronger in upper respiratory tract
19
20 360 than in lower respiratory tract. This could be explained by the large size of the pollen grain.
21
22 361 Generally, the size of pollen varies between 20 and 100 micrometers in diameter.[56] Therefore,
23
24 362 particles of pollen grain size do not penetrate well into the lower respiratory tract.[57] Pollen
25
26 363 grains are likely to adhere and release their allergenic content already in the upper respiratory
27
28 364 tract. As a consequence of this, the majority of the direct allergic inflammatory effects caused by
29
30 365 pollen may be experienced in the region of the upper respiratory tract.

31 366 Our systematic review did not detect any major effect of pollen exposure on lung function. The
32
33 367 results may be explained by the fact that the study population for lung function effects included
34
35 368 healthy people in addition to asthmatic and allergic subjects. If these studies would only include
36
37 369 asthmatic and/or allergic persons, more pronounced effects might be detected. In the Swedish
38
39 370 cohort-based study, exposure to grass pollen during the preceding day was associated with a
40
41 371 reduced forced expiratory volume in relation to an increase in three pollen counts (/m³) among
42
43 372 the 8-year-old children.[58] This association was more pronounced among children who were
44
45 373 sensitized to pollen allergens. In line with those results, another study of Swedish adults showed
46
47 374 that pollen exposure resulted in significantly increased concentration of nitric oxide in exhaled air,
48
49 375 which suggested increased airway inflammation among these asthmatics compared to the healthy
50
51 376 controls.[59]

52 378 **Conclusions**

53
54 379 This systematic review and meta-analysis provides new evidence that short-term exposure to
55
56 380 pollen grains increases any respiratory symptoms, as well as specifically upper respiratory and
57
58 381 ocular symptoms among asthmatic and allergic subjects. It is important that clinicians take into
59
60 382 account, when working with allergic and asthma patients that even relatively short-term exposure

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

383 to pollen can induce for them symptoms of allergies and asthma. Clinicians should advice allergic
384 and asthmatic subjects to avoid spending much time outdoors during the (main) pollen periods,
385 and to use adequate allergy and asthma medications when such exposures cannot be avoided.
386 Future studies should use personal exposure assessment and it would be important to find out
387 how the variation in pollen exposure affects the health of allergic and asthmatic subjects.

Acknowledgments

389 We thank Riitta Aittamaa for her valuable assistance with figure editing. We also thank the
390 organizing committee of the 6th European Symposium on Aerobiology held in Lyon, France, July
391 2016 to possibility to present the main results of the study.

Contributors

394 JJ and TH conceived the study; MK, DRY and TH reviewed the articles, NS and MK analyzed the
395 data under supervision of JJ; MK, TH, MJ, and JJ wrote the manuscript, all authors contributed to
396 the intellectual content and approved the final version

Data sharing statement

400 No additional data available.

Patient consent

403 Not required

Funding

405 This work was supported by the Research Council for Health, the Academy of Finland [grant
406 numbers 266314, 267675, 267995 (APTA Consortium) and 24302585 (GLORIA Consortium)], and
407 the University of Oulu Strategic Funding. The funders had no role in study design, data collection
408 or analysis, decision to publish, or preparation of the manuscript.

411 **Competing Interests** None declared.

1
2
3 414 **Legends to the figures**
4

5 415

6
7 416 **Figure 1** Flow diagram showing searches and study selection.
8

9 417

10 418 **Figure 2** Forest plot for the relation between pollen exposure and any symptom (Weights are from
11 random effects analysis).
12
13

14 420

15
16 421 **Figure 3 A** Forest plot for the relation between pollen exposure and lower respiratory symptoms
17 (Weights are from random effects analysis). **B.** Forest plot for the relation between pollen
18 422 exposure and upper respiratory symptoms (Weights are from random effects analysis). **C.** Forest
19 423 plot for the relation between pollen exposure and ocular symptoms (Weights are from random
20 424 effects analysis). **D.** Forest plot for the relation between pollen exposure and symptom score
21 (Weights are from random effects analysis).
22
23
24
25
26

27 427

28
29 428 **Supplementary File, Figure 1 A.** Forest plot for the relation between pollen exposure and peak
30 429 expiratory flow (PEF; Weights are from random effects analysis). **B.** Forest plot for the relation
31 430 between pollen exposure and forced expiratory volume (FEV; Weights are from fixed effects
32 431 analysis).
33
34

35 432

36
37 433 **Supplementary File, Figure 2** Funnel plot with pseudo 95% confidence limits for the relation
38 434 between short-term pollen exposure and any symptom.
39

40 435

41

42 436

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**REFERENCES**

1. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. *Allergy*2004;59:469–478.
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). *Allergy*2008;86:8–160.
3. Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. *Ther Adv Respir Dis*2012;6:11–23.
4. Ait-Khaled N, Pearce N, Anderson HR, et al. ISAAC Phase Three Study Group. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. *Allergy*2009;64:123–148.
5. Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to asthma control. *Eur Respir J*2015;46:622–639.
6. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. *Eur Respir J*2004;24:758–764.
7. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. *BMC Public Health*2012;12:204.
8. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. *Allergy Asthma Proc*2008;29:600–608.
9. National Health Interview Survey (NHIS) Data; Most Recent Asthma Data. The Centers for Disease Control and Prevention (CDC), 2016. https://www.cdc.gov/asthma/most_recent_data.htm (accessed 25 September 2018).
10. Wang XY, Ma TT, Wang XY, et al. Prevalence of pollen-induced allergic rhinitis with high pollen exposure in grasslands of northern China. *Allergy*2018;73(6):1232–1243.
11. Blomme K, Tomassen P, Lapeere H, et al. Prevalence of allergic sensitization versus allergic rhinitis symptoms in an unselected population. *Int Arch Allergy Immunol*2013;160:200–207.
12. Darrow LA, Hess J, Rogers CA, et al. Ambient pollen concentrations and emergency department visits for asthma and wheeze. *J Allergy Clin Immunol*2012;130(3):630–638.
13. Annesi-Maesano I, Rouve S, Desqueyroux H, et al. Grass pollen counts, air pollution levels and allergic rhinitis severity. *Int Arch Allergy Immunol*2012;158:397–404.
14. Feo Brito F, Mur Gimeno P, Carnés J, et al. Grass pollen, aeroallergens, and clinical symptoms in Ciudad Real, Spain. *J Investig Allergol Clin Immunol*2010;20(4):295–302.
15. DellaValle CT, Triche EW, Leaderer BP, et al. Effects of Ambient Pollen Concentrations on Frequency and Severity of Asthma Symptoms among Asthmatic Children. *Epidemiology*2012; 23(1):55–63.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

16. Taylor PE, Jacobson KW, House JM, et al. Links between pollen, atopy and the asthma epidemic. *Int Arch Allergy Immunol*2007;144:162–170.
17. Caillaud D, Thibaudon M, Martin S, et al. Short-term effects of airborne ragweed pollen on clinical symptoms of hay fever in a panel of 30 patients. *J Investig Allergol Clin Immunol*2014a;24(4):249–256.
18. Häfner D, Reich K, Matricardi PM, et al. Prospective validation of ‘Allergy-Control-SCORE™’: a novel symptom–medication score for clinical trials. *Allergy*2011;66:629–636.
19. Roberts G, Mylonopoulou M, Hurley C, et al. Impairment in quality of life is directly related to the level of allergen exposure and allergic airway inflammation. *Clin Exp Allergy*2005;35:1295–1300.
20. Delfino RJ, Zeiger RS, Seltzer JM, et al. Association of asthma symptoms with peak particulate air pollution and effect modification by anti-inflammatory medication use. *Environ Health Perspect*2002;110(10):A607–A617.
21. Ostro B, Lipsett M, Mann J, et al. Air pollution and exacerbation of asthma in African-American children in Los Angeles. *Epidemiology*2001;12:200–208.
22. Baraldi E, Carrà S, Dario C, et al. Effect of natural grass pollen exposure on exhaled nitric oxide in asthmatic children. *Am J Respir Crit Care Med*1999;159:262–266.
23. Delfino RJ, Zeiger RS, Seltzer JM, et al. The effect of outdoor fungal spore concentrations on daily asthma severity. *Environ Health Perspect*1997;105(6):622–635.
24. Ross MA, Persky VW, Scheff PA, et al. Effect of ozone and aeroallergens on the respiratory health of asthmatics. *Arch Environ Health*2002;57(6):568–578.
25. Scarlett JF, Abbott KJ, Peacock JL, et al. Acute effects of summer air pollution on respiratory function in primary school children in southern England. *Thorax*1996;51:1109–1114.
26. Studnicka MJ, Frischer T, Meinert R, et al. Acidic particles and lung function in children: a summer camp study in the Austrian Alps. *Am J Respir Crit Care Med*1995;151:423–430.
27. Roberts G, Hurley C, Bush A, et al. Longitudinal study of grass pollen exposure, symptoms, and exhaled nitric oxide in childhood seasonal allergic asthma. *Thorax*2004;59:752–756.
28. Caillaud D, Toloba Y, Raobison R, et al. Health impact of exposure to pollens: A review of epidemiological studies. [Article in French]. *Rev Mal Respir*2014b;31(2):142–149.
29. Newhouse CP, Levetin E. Correlation of environmental factors with asthma and rhinitis symptoms in Tulsa OK. *Ann Allergy Asthma Immunol*2004;92:356–366.
30. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. 2009. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med*6(7):e1000097.
31. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*1994;50(4):1088–1101.

- 1
2
3 509 32. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
4 510 graphical test. *BMJ*1997;315(7109):629–634.
- 6 511 33. Caillaud DM, Martin S, Segala C, et al. Nonlinear short-term effects of airborne Poaceae levels
7 512 on hay fever symptoms. *J Allergy Clin Immunol*2012;130(3):812–814.
- 9
10 513 34. Caillaud D, Martin S, Segala C, et al. Effects of airborne birch pollen levels on clinical symptoms
11 514 of seasonal allergic rhinoconjunctivitis. *Int Arch Allergy Immunol*2014c;163:43–50.
- 12
13 515 35. Delfino RJ, Coate BD, Zeiger RS, et al. Daily asthma severity in relation to personal ozone
14 516 exposure and outdoor fungal spores. *Am J Respir Crit Care Med*1996;154:633–641.
- 16 517 36. Djukanović R, Feather I, Gratiou C, et al. Effect of natural allergen exposure during the grass
17 518 pollen season on airways inflammatory cells and asthma symptoms. *Thorax*1996;51(6):575–581.
- 19
20 519 37. Domínguez-Vilches E, Cariñanos P, Galán Soldevilla C, et al. Airborne pollen concentrations,
21 520 solid particle content in the air and allergy symptoms in Córdoba (Spain).
22 521 *Aerobiologia*1995;11(2):129–135.
- 24 522 38. Feo Brito F, Mur Gimeno P, Martínez C, et al. Air pollution and seasonal asthma during the
25 523 pollen season. A cohort study in Puertollano and Ciudad Real (Spain). *Allergy*2007;62(10):1152–
26 524 1157.
- 28
29 525 39. Feo Brito F, Mur Gimeno P, Carnés J, et al. *Olea europaea* pollen counts and aeroallergen levels
30 526 predict clinical symptoms in patients allergic to olive pollen. *Ann Allergy Asthma
31 527 Immunol*2011;106(2):146–152.
- 33
34 528 40. Grammer L, Wiggins C, Shaughnessy MA, et al. Absence of nasal priming as measured by
35 529 rhinitis symptom scores of ragweed allergic patients during seasonal exposure to ragweed pollen.
36 530 *Allergy Proc*1990;11(5):243–246.
- 37
38 531 41. Jantunen J, Saarinen K, Rantio-Lehtimäki A. Allergy symptoms in relation to alder and birch
39 532 pollen concentrations in Finland. *Aerobiologia*2012;28:169–176.
- 41
42 533 42. Klabuschnigg A, Götz M, Horak F, et al. Influence of aerobiology and weather on symptoms in
43 534 children with asthma. *Respiration*1981;42(1):52–60.
- 44
45 535 43. Krämer U, Weidinger S, Darsow U, et al. Seasonality in symptom severity influenced by
46 536 temperature or grass pollen: results of a panel study in children with eczema. *J Invest
47 537 Dermatol*2005;124:514–523.
- 48
49 538 44. Petersen BN, Sandberg I. Diagnostics in allergic diseases by correlating pollen/fungal spore
50 539 counts with patient scores of symptoms. *Grana*1981;20:219–224.
- 52
53 540 45. Schäppi GF, Taylor PE, Kenrick J, et al. Predicting the grass pollen count from meteorological
54 541 data with regard to estimating the severity of hayfever symptoms in Melbourne (Australia).
55 542 *Aerobiologia*1998;14:29–37.
- 56
57 543 46. Taudorf E, Moseholm L. Pollen count, symptom and medicine score in birch pollinosis. A
58 544 mathematical approach. *Int Arch Allergy Appl Immunol*1988;86:225–233.
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 545 47. Riediker M, Keller S, Wüthrich B, et al. Personal pollen exposure compared to stationary
546 measurements. *J Investig Allergol Clin Immunol*2000;10(4):200–203.
- 547 48. Hugg TT, Hjort J, Antikainen H, et al. Urbanity as a determinant of exposure to grass pollen in
548 Helsinki Metropolitan area, Finland. *PLOS ONE*2017;12(10):e0186348.
- 549 49. Osborne NJ, Alcock I, Wheeler BW, et al. Pollen exposure and hospitalization due to asthma
550 exacerbations: daily time series in a European city. *Int J Biometeorol*2017;61(10):1837–1848.
- 551 50. Robertson DG, Kerigan AT, Hargreave FE, et al. Late asthmatic responses induced by ragweed
552 pollen allergen. *J Allergy Clin Immunol*1974;54(4):244–254.
- 553 51. D'Amato G, Cecchi L, Bonini S, et al. Allergenic pollen and pollen allergy in Europe.
554 *Allergy*2007;62(9):976–990.
- 555 52. Erbas B, Jazayeri M, Lambert KA, et al. Outdoor pollen is a trigger of child and adolescent
556 asthma emergency department presentations: A systematic review and meta-analysis.
557 *Allergy*2018;73(8):1632–1641.
- 558 53. Yoshida K, Adachi Y, Akashi M, et al. Cedar and cypress pollen counts are associated with the
559 prevalence of allergic diseases in Japanese schoolchildren. *Allergy*2013;68(6):757–763.
- 560 54. Guilbert A, Simons K, Hoebek L, et al. Short-term effect of pollen and spore exposure on
561 allergy morbidity in the Brussels-Capital region. *Ecohealth*2016; 13(2):303–315.
- 562 55. Gleason JA, Bielory L, Fagliano JA. Associations between ozone, PM2.5, and four pollen types
563 on emergency department pediatric asthma events during the warm season in New Jersey: a case-
564 crossover study. *Environ Res*2014;132:421–429.
- 565 56. Haahtela T, Sorsa P. Kasviallergiat ja allergiakasvit [Plant allergies and allergenic plants; in
566 Finnish]. Helsinki: *Kirjayhtymä* 1999.
- 567 57. Suphioglu C, Singh MB, Taylor P, et al. Mechanism of grass-pollen-induced asthma.
568 *Lancet*1992;339(8793):569–572.
- 569 58. Gruzieva O, Pershagen G, Wickman M, et al. Exposure to grass pollen--but not birch pollen--
570 affects lung function in Swedish children. *Allergy*2015;70(9):1181–1183.
- 571 59. Bake B, Viklund E, Olin AC. Effects of pollen season on central and peripheral nitric oxide
572 production in subjects with pollen asthma. *Respir Med*2014;108(9):1277–1283.

Page 25 of 39
Panel study AND
Pollen (N=152)

Scopus search:
Panel study AND
Pollen (N=306)

BMJ Open search:
Pollen (Mesh) AND
Cohort studies OR
Longitudinal studies
OR Follow-up
studies OR
Case-control studies
OR Cross-sectional
studies (Mesh)
AND Asthma
(Mesh) (N=151)

Scopus search:
Pollen exposure
AND Cohort study
OR Longitudinal
study OR
Follow-up study
OR Case-control
study (N=33)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

Obviously
irrelevant articles
(N=90)

Obviously
irrelevant articles
(N=208)

Obviously
irrelevant articles
(N=100)

Obviously
irrelevant articles
(N=15)

Articles excluded
for not meeting the
inclusion criteria
(N=56)

Articles excluded
for not meeting the
inclusion criteria
(N=88)

Articles excluded
for not meeting the
inclusion criteria
(N=50)

Articles excluded
for not meeting the
inclusion criteria
(N=16)

Total: 6 eligible
articles

Total: 10 eligible
articles

Total: 1 eligible
article

Total: 2 eligible
articles

Relevant articles
identified from
reference lists
(N=14)

Duplicate articles
excluded (N=7)

Articles included
in the systematic
review (N=26)


Articles included in the meta-analysis (N=12):
*Caillaud et al. 2012*³³
*Caillaud et al. 2014a*¹⁷
*Caillaud et al. 2014c*³⁴
*Delfino et al. 2002*²⁰
*DellaValle et al. 2012*¹⁵
*Feo Brito et al. 2007*³⁸
*Feo Brito et al. 2011*³⁹
*Ostro et al. 2001*²¹
*Roberts et al. 2005*¹⁹
*Ross et al. 2002*²⁴
*Scarlett et al. 1996*²⁵
*Supak et al. 1998*³⁵

Articles not included in the meta-analysis (N=14):
*Delfino et al. 1996*³⁵
*Delfino et al. 1997*²³
*Djukanovic et al. 1996*³⁶
*Dominguez-Vilches et al. 1995*³⁷
*Feo Brito et al. 2010*⁴⁴
*Grammer et al. 1990*⁴⁰
*Jantunen et al. 2012*⁴¹
*Klabuschnigg et al. 1981*⁴²
*Krämer et al. 2005*⁴³
*Newhouse & Levetin 2004*²⁹
*Petersen & Sandberg 1981*⁴⁴
*Roberts et al. 2004*⁴⁵
*Schäppi et al. 1998*³⁵
*Taudorf & Moseholm 1988*⁴⁶


Any symptom

BMJ Open


Page 26 of 39




per review only - <http://bmjopen.bmj.com/site/about/guideline>




B Upper respiratory symptoms



C Ocular symptoms



D Symptom score



Supplementary Table 1. Risk of bias tables.

Caillaud et al. 2012		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 71.1%; "43 volunteers were excluded, either because they failed to provide the requested daily health records (n=24) or because they did not fulfill the inclusion criteria (n=19)"
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

Caillaud et al. 2014a		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 96.8%; "One participant was excluded because he failed to provide the requested daily health records during the month of August and additionally he experienced hay fever before the pollen season."
Selective reporting (reporting bias)	Low risk	Protocol was not available but it was clear that all pre-specified and expected outcomes of interest were reported
Other bias	Low risk	There was some overlap among the study subjects, so that seven individuals (23% of participants) were included study groups in both years. "Of these 31 patients, 7 participated in the 2 years." Pos sensitized patients were involved.

		“It would have been preferable to include patients who were strictly monosensitized to <i>A. artemisiifolia</i> in order to obtain more accurate results regarding the relationship between pollen exposure and symptoms [31]. However, due to the rarity of monosensitized patients, the study had to include polysensitized patients.”
Caillaud et al. 2014c		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 85.9%; “Ten participants were excluded either because they failed to provide the requested daily health records (n=8) or because they did not qualify for inclusion (N=2).” Partly missing symptom data. “Missing symptom score data occurred on 285 person-days (8.6% of the total expected follow-up of 3,311 person-days) because subjects had left the study area all day...”
Selective reporting (reporting bias)	Low risk	Protocol was not available but it was clear that all pre-specified and expected outcomes of interest were reported
Other bias	Low risk	None were identified

Delfino et al. 2002		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design

Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 88.0%. “A 10-year-old boy and a 14-year-old girl dropped out after the second week of study and are not retained for analysis. One white 10-year-old male was asymptomatic throughout the panel period and therefore contributed no information to the repeated-measures analysis.” Partly missing symptom data. “Missing symptom score data occurred on 51 person-days (3.8% of total expected follow-up of 1,328 person-days) because subjects had left the study area all day, and on 29 person-days because of noncompliance with diary completion (2.2%), ...”
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

Della Valle et al. 2012		
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 92.3%; “We restricted the analysis to 430 subjects who completed an exit interview and who lived primarily within the northeastern U.S. throughout follow-up, ...”
Selective reporting (reporting bias)	Low risk	Protocol was not available but it was clear that all pre-specified and expected outcomes of interest were reported.
Other bias	Low risk	None were identified

Feo Brito et al. 2007		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 90.1%. "... seven patients withdrew in Puertollano and eight patients in Ciudad Real leaving a final study population of 137 patients ..."
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

Feo Brito et al. 2011		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 100%
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

Ostro et al. 2001		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design

Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 90.2%; “Five subjects who provided baseline data never provided any daily diary information. In addition, data from 10 subjects (representing 8.3% of the person-days) were excluded from the analysis because of evidence that the intake data or diary data were likely to have been inaccurate, or because the diaries were returned more than 2 weeks late.” Partly feasible symptom data. “A total of 10,022 person-days of symptom data were reported, of which we used 9,126 in the analysis after the health data of questionable validity were excluded.”
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

Roberts et al. 2005		
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 100%
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

For peer review only

Ross et al. 2002		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 67.8%. "Two families withdrew early in the study period, and a number of participants either withdrew later in the study or failed to provide the requested daily health records ... The 2 primary reasons stated for withdrawal from the study were a lack of time or interest in participating, or a move from the study area. Partly missing symptom data. "The last few days of data were excluded because of the small number of remaining participants."
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified



Scarlett et al. 1996		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk to high risk	Follow-up rate was 100%
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	High risk	Not feasible asthma medication data. "Children on medication for asthma were asked whether they had taken any medication that day. Unfortunately, the quality of these data were


		poor and so they were not used in the analysis. At worst this would bias the regression coefficients towards the null value.”
--	--	---

Studnicka et al. 1995		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 88.7%; “For three, five, and seven children, respectively, permission was denied (for the 1st, 2nd, and 3rd panel). For Panel 3, two children were not able to perform reproducible spirometry.”
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46







PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	2
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	4
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	9, FIG1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	9
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	study protocol
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	14
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	9



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	14
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	N/A
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICCO, follow-up period) and provide the citations.	Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Table 1
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	FIG2-FIG3, Suppl Fig1
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	FIG2-FIG3, Suppl Fig1
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	14
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	14-16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16-17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	18



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only

136/bmjopen-2019-029029 on 10 January 2020. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

BMJ Open

Short-term exposure to pollen and the risk of allergic and asthmatic manifestations: A systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029069.R2
Article Type:	Original research
Date Submitted by the Author:	19-Oct-2019
Complete List of Authors:	Kitinoja, Milja; University of Oulu, Center for Environmental and Respiratory Health Research Hugg, Timo; University of Oulu, Center for Environmental and Respiratory Health Research Siddika, Nazeeba; University of Oulu, Center for Environmental and Respiratory Health Research Rodriguez Yanez, Daniel; University of Oulu, Center for Environmental and Respiratory Health Research Jaakkola, Maritta; University of Oulu, Center for Environmental and Respiratory Health Research Jaakkola, Jouni; University of Oulu, Center for Environmental and Respiratory Health Research
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Respiratory medicine, Public health
Keywords:	Epidemiology < TROPICAL MEDICINE, Public health < INFECTIOUS DISEASES, Allergy < THORACIC MEDICINE, Asthma < THORACIC MEDICINE

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Short-term exposure to pollen and the risk of allergic and asthmatic manifestations:**
2 **A systematic review and meta-analysis**

3 Milja A. Kitinoja, BM,^{1,2} Timo T. Hugg, PhD,^{1,2} Nazeeba Siddika, DSc, MSc,^{1,2} Daniel Rodriguez
4 Yanez, BSc,^{1,2} Maritta S. Jaakkola, MD, PhD^{1,2}, Jouni J. K. Jaakkola, MD, PhD,^{1,2*}

5 ¹ Center for Environmental and Respiratory Health Research, P.O.Box 5000 (Aapistie 5B), FIN-
6 90014 University of Oulu, Oulu, Finland

7 ² Medical Research Center Oulu, Oulu University Hospital and University of Oulu, P.O.Box 5000
8 (Aapistie 5A), FIN-90014 University of Oulu, Oulu, Finland

9 * Correspondence: Professor Jouni J.K. Jaakkola, Center for Environmental and Respiratory Health
10 Research (CERH), University of Oulu, P.O. Box 5000 (Aapistie 5 B), 90014 Oulu, Finland;
11 Tel.:+358406720927, E-mail address: jouni.jaakkola@oulu.fi.

14 **Word count: text 3852, abstract 249**

32 ABSTRACT

33 **Background** Several studies have assessed effects of short-term exposure to pollen on allergic and
34 asthmatic manifestations. The evidence is inconclusive, and no meta-analysis has been published.

35 **Objective** To synthesize the evidence on the relations between short-term pollen exposure and the risk of
36 allergic and asthmatic manifestations.

37 **Methods** We performed a systematic literature search of PubMed and Scopus databases up to the end of
38 August 2018. In addition, we reviewed the reference lists of relevant articles. Two authors independently
39 evaluated the eligible articles and extracted relevant information in a structured form. We calculated
40 summary effect estimates (EE) based on the study-specific odds ratios and regression coefficients (β) by
41 applying both fixed- and random-effects models.

42 **Results** 26 studies met the *a priori* eligibility criteria, and 12 of them provided sufficient information for the
43 meta-analysis. The summary EE related to 10 grains per m³ increase in pollen exposure showed an 1%
44 increase (EE=1.01 95% CI 1.00 to 1.02) in the risk of lower respiratory symptoms and a 2% increase (EE=1.02
45 95% CI 1.01 to 1.03) in the risk of any allergic or asthmatic symptom. Correspondingly, the risk of upper
46 respiratory symptoms and ocular symptoms increased 7% (EE=1.07 95% CI 1.04 to 1.09) and 11% (EE= 1.11
47 95% CI 1.05 to 1.17), respectively, in relation to such pollen exposure. Short-term exposure to pollen did
48 not show any significant effect on daily lung function levels.

49 **Conclusion:** Our results provide new evidence that short-term pollen exposure significantly increases the
50 risks of allergic and asthmatic symptoms.

52 **Strengths and limitations of this study**

- 53 • Identification of individual studies based on a clearly defined and extensive search strategy based on a
54 priori set inclusion and exclusion criteria.
- 55 • In addition, secondary references were included
- 56 • The study-specific effect estimates were converted into comparable effect estimates for exposure
57 corresponding to 10 pollen grains increase per cubic meter.
- 58 • Publication bias was assessed by visual inspection of the funnel plots and by applying Begg's and Egger's
59 tests.
- 60 • The number of studies available for the sub-analyses investigating effects on various outcomes was quite
61 low.

63 **Keywords**

64 Allergy; asthma; panel study; pollen exposure; systematic review; meta-analysis

66 INTRODUCTION

67 Allergy and asthma are common diseases and consequently, of public health importance globally.
68 Approximately 500 million people suffer from allergic rhinitis worldwide and more than 300
69 million people have asthma.[1-3] The prevalence of rhinitis and/or rhinoconjunctivitis varies
70 globally between 1% and 45%[4] and that of asthma between 1% and 21%.[5] In Western Europe,
71 the prevalence of allergic rhinitis and/or rhinoconjunctivitis ranges from 17% to 29%[6] and the
72 prevalence of asthma from 6% to 18%.[7] Respectively, the prevalence of rhinitis and/or
73 rhinoconjunctivitis and asthma are 12–30%[8] and 5-10% in the U.S.[9]

74 The prevalence of physician-diagnosed pollen-induced allergic rhinitis was 18.5% among people
75 living in northern China.[10] The majority of individuals suffering from allergic rhinitis experience
76 seasonal symptoms when exposed to pollen.[11] Correspondingly, exposure to pollen grains
77 increases the risk of asthma exacerbations among asthmatic persons.[12] There are no universally
78 accepted, clinically meaningful threshold levels for pollen exposure. In previous studies, threshold
79 levels have varied between 30 and 60 pollen grains per cubic meter of air.[13,14] However,
80 exposures to relatively low levels of pollen (6-9 grains/m³) have been associated with asthma
81 symptoms among those who already have this disease.[15] Pollen allergy has been found in 80–
82 90% of children suffering from asthma and in 40–50% of adult-onset asthmatics.[16]

83 Several panel studies have suggested an association between short-term exposure to pollen and
84 allergic/asthmatic manifestations, although the magnitude and statistical significance of such
85 estimated relations have varied.[17-21] Lung function levels have not been found to clearly
86 associate with pollen exposure.[22-26] However, the amount of exhaled nitric oxide (NO)[22,27]
87 and allergy and/or asthma medication use[18,24] seem to increase during pollen season. Caillaud
88 et al.[28] reviewed qualitatively three panel studies that provided some evidence on a relation
89 between daily counts of atmospheric pollen and occurrence of health outcomes.

90 The panel studies on pollen exposure and manifestations of asthma or allergy have provided
91 somewhat conflicting results.[23,29] To our knowledge there are no previous systematic reviews
92 with meta-analysis that have assessed the effects of short-term pollen exposure on the risk of
93 allergic and asthmatic symptoms and lung function. Therefore, we conducted a systematic review
94 and meta-analysis to summarize the existing evidence on the relations between short-term
95 exposure to pollen and the occurrence of various allergic and asthmatic symptoms and/or lung
96 function manifestations.

METHODS

This systematic review and meta-analysis is based on a review protocol accessible online (<http://www.oulu.fi/cerh/node/50459>).

Search strategy and eligibility criteria

We performed a systematic literature search of PubMed and Scopus databases up to the end of August 2018, as shown in figure 1. In the first phase, we used the search terms “panel study” and “pollen”. In order to have a more extensive data search, we included the terms “pollen exposure”, “asthma”, “cohort study”, “longitudinal study”, “follow-up study”, “case-control study” and “cross-sectional study” in the second search (Supplementary Table 1). All languages were included in the search.

Studies that met the following *a priori* eligibility criteria were included in this systematic review: the study (1) was an original study; (2) was a panel study where a group of people were followed longitudinally over a certain time period; (3) included allergic or asthmatic symptoms or measurements of lung function as the outcome; (4) included a study population of children or adults or both; and (5) reported on relations between daily mean airborne pollen exposure and manifestations of allergies and/or asthma.

Articles that were obviously irrelevant were excluded applying title screening. Articles that did not meet our *a priori* inclusion criteria were excluded by reading the abstract or full text.

Outcome and exposure definitions

The outcome of interest was occurrence of allergy and/or asthma manifestations. The definitions of allergy and asthma manifestations included self- or parent-reported symptoms (lower and upper respiratory tract symptoms, ocular symptoms, skin symptoms and/or symptom scores), lung function measurements (Peak expiratory flow, PEF, Forced expiratory volume, FEV, Forced vital capacity, FVC, Exhaled nitric oxide, NO), and use of allergy and/or asthma medications. The exposure of interest was exposure to pollen, expressed as the amount of pollen grains per cubic meter of air sampled (grains/m³). The eligible definition of exposure included exposure to mean daily total airborne pollen or exposure to mean daily airborne pollen of distinct types (including birch, grass, ragweed, mugwort, olive, elm and/or hazel/alder pollen). All the available studies assessed the associations between pollen concentrations and symptoms during the same day, i.e. the duration of short-term exposure was here one day.

1
2
3 129
4
5 130
6
7 131
8
9 132
10
11 133
12
13 134
14
15 135
16
17 136
18
19 137
20
21 138
22
23 139
24
25 140
26
27 141
28
29 142
30
31 143
32
33 144
34
35 145
36
37 146
38
39 147
40
41 148
42
43 149
44
45 150
46
47 151
48
49 152
50
51 153
52
53 154
54
55 155
56
57 156
58
59 157
60 158

Data extraction and quality assessment

Eligible studies were examined and their relevant characteristics recorded in a standardized data extraction form independently by two authors (M.A.K. and D.R.Y.). Any disagreements were discussed together with additional two authors at the end of the data extraction process (T.T.H. and J.J.K.J.) until a consensus was achieved. Table 1 displays the main characteristics of the eligible studies. The study quality was assessed applying the Newcastle-Ottawa Scale (NOS) with the maximum score of 9.

In one study, the occurrence of allergic and asthmatic symptoms in relation to pollen exposure was investigated by recruiting a group of study subjects in two consecutive years.[17] There was some overlap among the study subjects, so that seven individuals (23% of participants) were included in both of these study groups. These two groups provided independent effect estimates (EE) for our meta-analysis. In another study, subjects were recruited in three distinct but successive periods of time within the pollen season.[26] These three groups also provided three independent effect estimates for the meta-analyses. The protocol was conducted according to PRISMA guidelines.[30]

Statistical methods

In the meta-analysis, we calculated summary effect estimates (EEs) from the study-specific odds ratios (OR) or regression coefficients (β) by using fixed- and random-effects models. When available, we preferred the adjusted EEs to the crude estimates. The summary EE from the fixed-effects model is presented when the study-specific EEs were homogenous, whereas the summary EE from the random-effects model is presented when moderate or substantial heterogeneity was observed between the study-specific estimates. Heterogeneity was evaluated using the Q- and I²-statistics. I²-statistic >50% indicates high, 25-50% moderate and <25% low heterogeneity. Publication bias was assessed by visual inspection of the funnel plots and application of Begg's and Egger's tests.[31,32] Individual studies included in the meta-analysis assessed their EEs in relation to different levels of pollen exposure. Because of this, individual EEs were converted into a common pollen concentration, i.e. as 10 pollen grains increase per cubic meter of air, before estimating the summary effect.

Because of only a small number of studies or inadequacy of data in the existing studies, we were not able to analyze potential relations between pollen exposure and skin symptoms, forced vital

1
2
3 161 capacity (FVC), exhaled NO or allergy and/or asthma medications. The panel studies with allergic
4
5 162 and/or asthmatic populations examined usually allergy- and asthma-related symptoms as
6
7 163 outcomes. In panel studies including general populations, the outcomes were lung function
8
9 164 measurements. We used the “metan” command of the Stata 11 statistical program to analyze the
10
11 165 fixed and random effects (StataCorp, College Station, Tex).

12 166 13 14 167 **Patient and public Involvement**

15
16 168 Due to nature of systematic review and meta-analysis, there was no patient and public
17
18 169 involvement in this study.

19 20 170 21 171 **RESULTS**

22 172 **Literature search**

23 173 Reference lists of the articles that fulfilled the eligibility criteria were also reviewed and additional
24
25 174 14 articles fulfilling the criteria were included. Seven duplicate studies were excluded. A step-by-
26
27 175 step approach of the literature search is presented in figure 1. Twenty-six studies met the *a priori*
28
29 176 inclusion criteria and were included in the systematic review, while 12 studies of them were
30
31 177 included in the quantitative meta-analysis. Table 1 displays the characteristics of the 26 eligible
32
33 178 studies.[14,15,17,19-21,23-27,29,33-46]

34 179 Ten of the 26 studies specifically investigated the relation between total pollen exposure and
35
36 180 allergic and/or asthmatic manifestations. Thirteen reported on grass (*Poaceae*), 5 on birch
37
38 181 (*Betula*), 5 on ragweed (*Ambrosia*), 3 on hazel/alder (*Corylus/Alnus*), 3 on olive (*Olea*), 2 on elm
39
40 182 (*Ulmus*), and 1 on mugwort (*Artemisia*) exposure and allergy and/or asthma manifestations.
41
42 183
43
44 184
45
46 185
47
48
49
50
51
52
53
54
55
56
57
58
59
60

186 **Table 1** Characteristics of the eligible studies included in the systematic review and meta-analysis (n = 26).

Reference (Region, country)	Study population	Study size (number of participants)	Follow-up (length and rate, %)	Outcomes	Method for pollen exposure assessment and the range of exposure expressed as mean daily pollen concentrations (pollen grains/m ³ of air)	NOS quality score ^a
Caillaud et al., 2012 ³³ (France and Switzerland)	Adults with hay fever sensitized to grass pollen	106	17 weeks; 71.1%	Self-reported ocular, nasal and lower respiratory symptoms	Regional monitoring by a volumetric pollen trap; range 0-133	4/9
Caillaud et al., 2014a ¹⁷ (France and Switzerland)	Adults with seasonal rhinitis sensitized to ragweed pollen	16 in 2009, 22 in 2010, a total of 30	11 weeks; 96.8%	Self-reported daily SAR symptoms: ocular (itching and/or tear flow and/or conjunctival redness), nasal (sneezing and/or runny nose and/or blocked nose) and respiratory (cough and/or wheezing and/or asthma) symptoms, use of medication	Regional monitoring by a volumetric pollen trap located 15 meters above the ground level; range 0-543	6/9
Caillaud et al., 2014c ³⁴ (France and Switzerland)	Adults with seasonal rhinitis sensitized to birch pollen	61	8 weeks; 85.9%	Self-reported daily SAR symptoms: ocular (itching and/or tear flow and/or conjunctival redness), nasal (sneezing and/or runny nose and/or blocked nose) and respiratory (cough and/or wheezing and/or asthma) symptoms	Regional monitoring by a volumetric pollen trap located 15 meters above the ground level; range 0-400-	5/9
Delfino et al., 1996 ³⁵ (US)	9-18 years old subjects with physician-diagnosed asthma	12	6 weeks; 80.0%	Asthma symptoms (wheeze, cough, sputum production, shortness of breath, chest tightness) and use of as-needed beta-agonist inhalers	Regional monitoring by a volumetric pollen trap located 10 meters above the ground level; range 4-115	4/9
Delfino et al., 1997 ²³ (US)	9-46 years old subjects with physician-diagnosed asthma sensitized to tree, grass or weed pollen	22	8 weeks; 91.7%	Self-reported daily asthma symptoms (cough, wheeze, sputum production, shortness of breath, and chest tightness), each evening and morning three PEF blows and daily asthma medication use (i.e. beta-agonist inhaler)	Regional monitoring by a volumetric pollen trap located 4 meters above the ground level; range 11-611	5/9

Delfino et al., 2002 ²⁰ (US)	9-19 years old subjects with physician-diagnosed asthma	22	8 weeks; 88.0%	Self-reported daily asthma symptoms (cough, wheeze, sputum production, shortness of breath, and chest tightness)	Regional monitoring by a volumetric pollen trap located 4 meters above the ground level; range 12-1257	5/9
DellaValle et al., 2012 ¹⁵ (US)	4-12 years old children with physician-diagnosed asthma	430	24-26 weeks during the years 2000-2004; 92.3%	Self-reported daily asthma symptoms (wheeze, night symptoms, shortness of breath, chest tightness, and persistent cough), use of asthma medication	Personal pollen exposure assessment based on modeling; range 0-4187	5/9
Djukanović et al., 1996 ³⁶ (United Kingdom)	20-49 years old adults with atopic asthma	17	15 weeks; 94.1%	Self-reported asthma symptoms (nocturnal wheeze, nocturnal cough, morning chest tightness, day-time wheeze, subjective worsening of asthma due to exercise, cold air or fumes), self-reported morning and evening PEF values, FEV1	Not specified; range 0-318 (based on weekly pollen counts)	1/9
Dominguez-Vilches et al., 1995 ³⁷ (Spain)	Patients with pollen induced allergic rhinitis	70 in 1991 and 23 in 1992	12 weeks in 1991 and 12 weeks in 1992; 70.0% in 1991 and 46.0% in 1992	Daily conjunctival, nasal and respiratory symptoms	Regional monitoring by a volumetric pollen trap placed on the roof of a university building; ranges of pollen concentrations are not clearly stated	2/9
Feo Brito et al., 2007 ³⁸ (Spain)	Subjects with mild to moderate seasonal asthma sensitized to grass and/or olive pollen	137	6 weeks; 90.1%	Self-reported symptoms of asthma, self-reported morning and evening PEF values	Regional monitoring by a volumetric pollen trap; ranges 1-550 (grasses) and 0-596 (olive)	4/9
Feo Brito et al., 2010 ¹⁴ (Spain)	10-51 years old patients with seasonal rhinitis and/or asthma, mono-sensitized to grass pollen	27	52 weeks; 100%	Self-reported symptoms / symptom and medication scores (including nasal obstruction, runny nose, sneezing/congestion, itching of the eyes, asthma attacks, use of medication)	Regional monitoring by a volumetric pollen trap located 5 meters above the ground level; range 0-585	2/9
Feo Brito et al., 2011 ³⁹ (Spain)	10-51 years old patients with seasonal rhinitis or asthma mono-sensitized to olive pollen	20	52 weeks; 100%	Self-reported symptoms (including conjunctival, nasal and respiratory symptoms)	Regional monitoring by a volumetric pollen trap located 15 meters above the ground level; range 0-443	3/9

Grammer et al., 1990 ⁴⁰ (US)	Patients with history of ragweed rhinitis	29	10 weeks; 100%	Self-reported daily symptoms / symptom medication scores (nasal congestion, nasal discharge, sneezing, ocular pruritus, cough, use of medication)	Not specified; A rotating arm impactor and weekly pollen data were used; range 0-2100	2/9
Jantunen et al., 2012 ⁴¹ (Finland)	8-70 years old persons with physician-diagnosed birch pollen allergy (rhinoconjunctivitis)	28 in 2009 and 33 in 2010	8 weeks; 95.3%	Self-reported symptoms (conjunctival symptoms [itchy, swollen, watery, or sore eyes], nasal symptoms [sneezing, runny, itchy, or blocked nose], other allergy symptoms), use of medication	Regional pollen monitoring by a volumetric pollen trap located 14 meters above the ground level; ranges 0-1970 (alders) and 0-6890 (birches)	3/9
Klabuschnigg et al., 1981 ⁴² (Austria)	7-14 years old children with clinically-diagnosed asthma	40	6 weeks; 92.5%	Self-reported asthma symptoms, lung function (PEF, FEV1, FVC) measured every second day, use of medication	Regional pollen monitoring by a volumetric pollen trap located 12 meters above the ground level; ranges of pollen concentrations are not clearly stated	2/9
Krämer et al., 2005 ⁴³ (Germany)	9 years old children with diagnosed allergic eczema	39	26 weeks; 69.6%	Self-reported daily eczema symptoms: itching and the extent of skin lesions	Regional pollen monitoring by a volumetric pollen trap located 12 meters above the ground level; ranges 0-215 (haze/alder), 0-1673 (birches), 0-184 (grasses) and 0-10 (mugworts)	5/9
Newhouse & Levetin, 2004 ²⁹ (US)	9-64 years old patients with physician-diagnosed asthma	24	8 weeks; 63.2%	Self-reported asthma symptoms, morning and evening PEF values	Regional pollen monitoring by a volumetric pollen trap located on the roof of a university building; ranges 1-498 (ragweeds), 0-167 (elms), 0-13 (grasses)	3/9
Ostro et al., 2001 ²¹ (US)	8-13 years old children with physician-diagnosed asthma	138	13 weeks; 90.2%	Self-reported daily asthma symptoms (shortness of breath, cough, and wheeze)	Pollen monitoring by a Rotod device (taking a sample for 30 seconds every 10 minutes); range 1-75	5/9
Petersen & Sandberg, 1981 ⁴⁴ (Denmark)	Patients suffering from diagnosed pollen allergy	78	36 weeks; 83.2%	Daily scoring of symptoms and use of medication; before, during and after pollen season	Regional pollen data; range 0-1600 (based on weekly pollen counts)	3/9

Roberts et al., 2004 ²⁷ (United Kingdom)	7-16 years old children with mild to moderate seasonal allergic asthma and rhinoconjunctivitis sensitized to grass pollen	44	10 weeks; 100%	Exhaled NO –measurements and FEV1	Regional pollen monitoring by a volumetric pollen trap; range 0-178	4/9
Roberts et al., 2005 ¹⁹ (United Kingdom)	6-17 years old children with seasonal allergic rhinoconjunctivitis, asthma and/or eczema sensitized to grass pollen	84	12 weeks; 100%	Self-reported weekly pediatric allergic disease quality based on life questionnaire, symptoms (chest, nasal, ocular, cutaneous and other symptoms) and emotional problems	Regional pollen monitoring by a volumetric pollen trap; ranges of pollen concentrations are not clearly stated	3/9
Ross et al., 2002 ²⁴ (US)	5-49 years old subjects with asthma	40	26 weeks; 67.8%	Self-reported morning and evening PEF, symptom score, occurrence of asthma attacks and frequencies of asthma medication use	Local pollen monitoring by Rotorod devices located 2 meters above the ground level; range 0-1492	4/9
Scarlett et al., 1996 ²⁵ (United Kingdom)	7-11 years old children with and without asthma	154	6 weeks; 100%	Daily lung function measurements (FEV0.75, FVC, FEV0.75/FVC)	Regional pollen monitoring, pollen counts were derived from the local monitoring site; range 2-183	6/9
Schäppi et al., 1998 ⁴⁵ (Australia)	17-50 years old volunteers with moderate to severe hay fever sensitized to grass pollen	21	3 weeks; 75.0%	Nasal (blockage, discharge or itching) and eye symptom scores (itching, swelling or running)	Regional pollen monitoring by a volumetric pollen trap located 14 meters above the ground level; range 0-400	3/9
Studnicka et al., 1995 ²⁶ (Austria)	7 years old and older children with and without asthma	47 in panel 1, 45 in panel 2, 41 in panel 3	3 weeks; 88.7%	Daily lung function measurements (FEV1, FVC, PEF)	Regional pollen monitoring by a volumetric pollen trap located 10 meters above the ground level; ranges of pollen concentrations are not clearly stated	7/9
Taudorf & Moseholm, 1988 ⁴⁶ (Denmark)	16-47 years old pollinotic (hay fever) patients sensitized to birch pollen	15	16 weeks in 1983 and 16 weeks in 1984; 75.0%	Nose and eye symptom scores, use of medication	Regional pollen monitoring by a volumetric pollen trap; ranges of pollen concentrations are not clearly stated	3/9

SAR, Seasonal allergic rhinitis. PEF, Peak expiratory flow. FEV1, Forced expiratory volume in the first second. FVC, Forced vital capacity. NO, Nitric oxide. FEV0.75, Forced expiratory volume at 3/4 of a second. ^a For panel studies, the maximum score is 7/9.

1

2

3 190 **Characteristics of included studies**

4

5 191 Characteristics of the 26 eligible studies are shown in table 1. In 13 studies subjects were
6
7 192 asthmatics, in 11 studies subjects were sensitized to pollen (i.e. positive Skin prick test, SPT or
8
9 193 Allergen-Specific Immunoglobulin E Test, IgE test) and in 8 studies subjects had hay fever (i.e.
10
11 194 allergic rhinitis, pollen allergy, pollinosis). One study investigated subjects with eczema. In 2
12
13 195 studies, subjects with and without asthma were analyzed together without taking into account the
14
15 196 prior disease status. Ten studies investigated children, four adults, and 9 both children and adults.
16
17 197 In 3 studies, authors did not specify the age of the subjects. Six studies applied logistic regression,
18
19 198 9 studies linear regression, 2 studies Poisson regression, and 2 studies time series regression for
19
20 199 the analyses. The NOS scores varied between studies from one to seven of total nine.

21

22 200 The studies defined the allergic and/or asthmatic manifestations in different ways. Sensitization
23
24 201 based on SPT or IgE analysis was the most common criterion used for the definition of allergy.
25
26 202 Current presence of asthma, previous history of asthmatic symptoms, and/or physician (i.e.
27
28 203 clinical) diagnosis were frequently applied as inclusion criteria in the reviewed studies. We
29
30 204 systematically categorized outcomes into any symptom, lower respiratory tract symptoms, upper
31
32 205 respiratory tract symptoms, ocular symptoms, skin symptoms, symptom scores, lung function
33
34 206 measurements (PEF, FEV, FVC and exhaled NO), and use of allergy and/or asthma medications.

35

36 207 Pollen monitoring used for exposure assessment was based on regional sampling in 21 studies,
37
38 208 on local sampling in 2 studies, and on personal exposure modelling in one study. In 2 studies,
39
40 209 authors did not specify the type of pollen sampling. The height of the pollen sampler varied
41
42 210 between 2-15 meters above the ground level. Thirteen of the studies did not give the height
43
44 211 information for pollen sampler. Twenty-five studies expressed the mean pollen concentration as
45
46 212 pollen grains per cubic meter of air per 24 h. In 3 studies, daily pollen counts were converted into
47
48 213 weekly pollen sums, and consequently, the relations between weekly pollen counts and weekly
49
50 214 symptoms were presented. In 2 studies, hourly/bihourly pollen counts were presented in addition
51
52 215 to daily counts. Main outcomes for the studies that were not included into the meta-analysis are
53
54 216 presented in table 2.

55

56 217

57 218 **Risk of bias across the studies**

58

59 219 In the majority of studies, exposure assessment was based on single stationary regional sampler
60
61 220 located on the roof level (Table 1). Although it has been suggested that different types of pollen
62
63 221 sampling can be used to get a rough estimate of pollen exposure,[47] many of the approaches may

1
2
3 222 not have captured the daily individual exposures at the breathing level in satisfactory detail. In
4
5 223 2013, we monitored grass pollen concentrations at 16 sites in the cities of Helsinki and Espoo
6
7 224 during the peak pollen season by using rotorod-type samplers at the breathing height.[48] We
8
9 225 identified substantial variation in exposure concentrations at breathing height according to
10
11 226 urbanity of the site and time of the day within areas covered by our roof level monitoring stations.
12
13 227 Most valid estimates of pollen exposure could be obtained by using personal pollen sampling.
14
15 228 There were also other potential sources of heterogeneity in the exposure measured by these
16
17 229 studies linked to variation in weather/climatic conditions, type and period of monitoring, nature of
18
19 230 pollen season, daily activities/time spent outdoors by the study subjects, variation in the height of
20
21 231 monitoring and pollen types monitored. This heterogeneity in exposure can generate a substantial
22
23 232 variation in occurrence and severity of symptoms among exposed subjects. Therefore, we
24
25 233 converted individual effect estimates into a common (comparable) pollen concentration, i.e. as 10
26
27 234 pollen grains increase per cubic meter of air.

27 235 In all studies, selection of study subjects was based on predefined and justified eligibility criteria.
28
29 236 Due to the study design that included inference based on within-individual variation of health
30
31 237 outcome, the risk of selection bias is rather small (Supplementary table 2). Also the relatively high
32
33 238 follow-up rates (varying from 46.0 to 100%) across studies reduce the risk of selection bias.
34
35 239 However, there was substantial diversity in the type and measurement of outcomes, which
36
37 240 resulted in difficulties in forming the major outcome groups for the meta-analyses. Status of
38
39 241 allergic and/or asthmatic diseases varied from mild to moderate or from moderate to severe.

40 242 The studies could be divided roughly into two major groups on the basis of what kind of
41
42 243 adjustment was applied for confounding. The first group of studies provided only descriptive
43
44 244 results without any or only with very basic statistical analyses. The second group performed
45
46 245 extensive statistical analyses, including controlling for a few or several confounders. Due to study
47
48 246 design where individuals act as their own controls on days with no (major) exposure, individual
49
50 247 characteristics were not potential confounders. In contrast, environmental factors, such as
51
52 248 temperature and air pollution can be potential confounders. A significant number of the studies
53
54 249 adjusted for temperature (13) and other meteorological parameters (12), as well as for air
55
56 250 pollution (4). Other potential sources of heterogeneity include variation in the studied time lags
57
58 251 between the exposure and the outcome (varying from 0 to 14 days), potential differences in
59
60 252 allergen content of pollen of interest, and different characteristics and size of the study
60 253 populations (varying from 12 to 430 subjects). In 24 studies, the study focused on asthmatics

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

254 and/or subjects with allergies, whereas two studies included both healthy and non-healthy
255 subjects.[25,26]

For peer review only

256 **Table 2** The main findings in articles not included into the meta-analysis (n = 14)

Reference	Main findings
Delfino et al. 1996 ³⁵	Pollen exposure was not associated with either asthma symptom scores or as-needed beta-agonist inhaler use.
Delfino et al. 1997 ²³	Pollen exposure was not associated with asthma symptom severity, morning or evening peak expiratory flow rate (PEFR), or β -agonist inhaler use.
Djukanovic et al. 1996 ³⁶	The peak pollen season was associated with a significant increase in asthma symptoms (P<0.05).
Dominguez-Vilches et al. 1995 ³⁷	A greater seasonal pollen intensity was associated with a higher occurrence of daily symptoms.
Feo Brito et al. 2010 ¹⁴	A significant positive association was found between the presence of symptoms and pollen grains (r=0.62; P<0.001).
Grammer et al. 1990 ⁴⁰	The peak pollen periods were associated with a twofold increase in symptom-medication scores among a subset of patients.
Jantunen et al. 2012 ⁴¹	The number of subjects with allergy symptoms increased significantly with the daily pollen concentrations (r = 0.35-0.36, P<0.01).
Klabuschnigg et al. 1981 ⁴²	Two hourly pollen counts or daily pollen counts were not associated with the frequency of asthma attacks. In contrast, consecutive 10-day mean symptom scores (assessing asthma attacks) associated with the total pollen counts. No associations were found between pollen exposure and lung function measurement (including PEF, FEV1 and FVC).
Krämer et al. 2005 ⁴³	Pollen exposure had no significant effect on skin symptom severity among children with winter type eczema (relative change in grass pollen exposure 0.98-1.00; 95% confidence limits 0.81-1.18). In contrast, grass-pollen exposure showed a significant effect on the severity of skin symptoms among children with summer type eczema (relative change in grass pollen exposure 1.16-1.19; 95% confidence limits 1.02-1.39).
Newhouse & Levetin 2004 ²⁹	<i>Ambrosia</i> pollen concentrations were significantly correlated with composite asthma scores (r=0.263, P<0.05), rhinitis scores (r=0.513, P<0.001) and several individual symptoms. <i>Chenopodiaceae/Amaranthaceae</i> pollen concentrations showed significant associations with composite asthma scores (r=0.256, P<0.05). <i>Urtica</i> (r=0.367, P<0.01), <i>Chenopodiaceae/Amaranthaceae</i> (r=0.458, P<0.001) and <i>Poaceae</i> (r=0.326, P<0.05) pollen concentrations showed significant correlations with composite rhinitis scores. Pollen concentrations significantly influenced morning (but not evening) PEF values measured in the following day (r=-0.261--0.364, P<0.05-0.01).
Petersen & Sandberg 1981 ⁴⁴	There was a positive association between the appearance of pollen grains in the air and the symptom-medication score.
Roberts et al. 2004 ²⁷	Fractional exhaled nitric oxide (FENO) levels increased significantly during the grass pollen season (median change 2.9 ppb, 95% confidence interval 1.5-5.4). There were no apparent associations between pollen counts and other lung function measurements.
Schäppi et al. 1998 ⁴⁵	The grass pollen counts associated significantly with the average nasal (r=0.637, P<0.001) and eye symptom (r=0.586, P<0.005) scores.
Taudorf & Moseholm 1988 ⁴⁶	Occurrence of symptoms and daily medication increased during the season with a constant pollen load.

1
2 257 PEFR, Peak expiratory flow rate = PEF, Peak expiratory flow. FEV1, Forced expiratory volume in the first second. FVC, Forced vital capacity. FENO, Fractional
3 258 exhaled nitric oxide.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

Relations between pollen exposure and allergy- and asthma-related symptoms among allergic / asthmatic subjects

A total of 12 studies were included in the meta-analyses. In 8 studies [15,17,20,21,33,34,38,39] the effect estimate was based on odds ratio and in 4 studies [19, 24-26] on a regression coefficient which was or was converted to a change per 10 grains per m³ of air. The summary EE for the relation between pollen exposure and any symptoms was statistically significantly increased at 1.02 (95% confidence interval (CI): 1.01-1.03) from the random effects model (figures 2, 3 and Supplementary File, figure 1). The study-specific estimates showed high heterogeneity. This estimate was based on 6 studies (providing 9 EEs). The funnel plot and the results from the Begg's (z= -1.25; P value= 0.211) and Egger's tests (Bias coefficient .0457453; 95% CI -.0048418-.0963324; P value= 0.070) on short-term pollen exposure and any symptoms provided no indication of publication bias (Supplementary File, figure 2).

A total of 6 studies (9 EEs) provided study-specific EEs for pollen exposure and lower respiratory symptoms. The summary EE from the random effects model was 1.01 (95% CI: 1.00-1.02). The study-specific estimates showed high heterogeneity.

The summary EE for pollen exposure and upper respiratory symptoms, based on 3 studies (4 EEs), was significantly increased at 1.07 (95% CI: 1.04-1.09) from the random effects model. There was moderate heterogeneity between the study-specific estimates.

The relation between pollen exposure and ocular symptoms was reported in 3 studies (4 EEs). The summary EE from the random-effects model was 1.11 (95% CI: 1.05-1.17). The study-specific estimates showed high heterogeneity.

The relation between pollen exposure and symptom scores was based on 4 studies applying linear regression modelling (giving regression coefficients). The summary EE was significantly elevated (1.003; 95% CI: 1.001-1.004). The study-specific estimates showed high heterogeneity.

Relations between pollen exposure and lung function among general population

The relation between pollen exposure and peak expiratory flow (PEF) was assessed in 2 studies (giving 4 EEs), resulting in a summary EE of 0.98 for 10 pollen grains increase per cubic meter of air (95% CI: 0.95-1.01) in the random effects model based on linear regression modelling. The study-specific estimates showed large heterogeneity.

Two studies estimated the relation between pollen exposure and forced expiratory volume (FEV). One study used forced expiratory volume in the first second, FEV₁ as the outcome and the

1
2
3 291 other forced expiratory volume at 3/4 of a second, FEV_{0.75}. Different FEV estimates were
4
5 292 combined in the analysis. Meta-analysis gave the summary EE of 1.00 for 10 pollen grains increase
6
7 293 per cubic meter of air (95% CI: 0.99-1.01) in the fixed effects model based on linear regression
8
9 294 modelling. There was little heterogeneity between the studies.

10
11 295

12 296 **Relations between pollen exposure and use of allergy and/or asthma medication**

13
14 297 In 2 studies, the use of allergy and/or asthma medication was combined with information on
15
16 298 allergy and/or asthma symptoms (in forming symptom-medication score). In 5 studies that
17
18 299 investigated the relation between pollen exposure and the use of medication, pollen exposure
19
20 300 increased the use of medication. In contrast, 3 studies did not show any association between
21
22 301 pollen exposure and use of allergy/asthma medication.

23 302

25 303 **DISCUSSION**

27 304 **Main findings**

28
29 305 This systematic review and meta-analysis provides new evidence that short-term pollen exposure
30
31 306 significantly increases the risk of allergic and asthmatic symptoms. The summary EE for a 10 grains
32
33 307 /m³ increase in pollen exposure showed on average a 2% increase in the risk of any allergic or
34
35 308 asthmatic symptom. The corresponding increases in the risk of upper respiratory symptoms and
36
37 309 ocular symptoms were 7% and 11%, respectively. All summary EEs were statistically significant.
38
39 310 This meta-analysis did not show any statistically significant relations between pollen exposure and
40
41 311 lung function measurements. The summary EE for 10 grains /m³ increase in pollen exposure
42
43 312 indicated a 2% decrease in PEF values, while no change was detected in relation to FEV values.

44 313

45 314 **Validity of results**

46
47 315 The strengths of our study include identification of individual studies based on a clearly defined
48
49 316 search strategy. In addition to the primary PubMed and Scopus database searches, we also used
50
51 317 secondary references that were cited by the articles and reviews identified in the primary search
52
53 318 to achieve as complete set of studies as possible. Two reviewers checked independently the
54
55 319 eligibility of the studies according to *a priori* set inclusion and exclusion criteria and identified the
56
57 320 most appropriate effect estimate.

58 321 The present systematic review and meta-analysis focused on panel studies mainly with relatively
59
60 322 brief follow-up periods. The follow-up periods in the studies varied from 3 weeks to 52 weeks.

1
2
3 323 However, pollen related allergic and asthmatic symptoms are usually induced after only a few
4
5 324 hours or days of exposure.[49,50] Thus, variable and/or relatively short follow-up periods are
6
7 325 probably not problematic when assessing the relationship between pollen exposure and outcomes
8
9 326 of interest in this study.

10
11 327 Our statistical analyses included 12 studies, because only 12 studies out of a total of 26
12
13 328 presented the exact mean or interquartile range (IQR) values of pollen grains per cubic meter.
14
15 329 Information on the mean and IQR values were needed to convert the study-specific effect
16
17 330 estimates into common effect estimates for exposure corresponding to 10 pollen grains increase
18
19 331 per cubic meter. The aim of this transformation was to make studies containing different pollen
20
21 332 concentration values comparable. Although the total number of panel studies was reasonable, the
22
23 333 numbers of studies available for the sub-analyses investigating various outcomes were quite low.
24
25 334 Therefore, the conclusions based on results of the sub-analyses should be interpreted with
26
27 335 caution. NOS scoring gave varying values, indicating partly the low quality of included studies.
28
29 336 Although it can reduce the confidence of the results, we did not see any major difference between
30
31 337 the effect estimates of the lower and higher scored studies.

32
33 338 "Any exposure" was applied in the analyses due to the heterogeneity of exposure assessment.
34
35 339 Total daily mean pollen concentration values were preferred, but when such were not available,
36
37 340 information on the mean daily airborne concentration of distinct pollen types (birch, grass,
38
39 341 ragweed, mugwort, olive, elm and/or hazel/alder) was used as the measure of exposure in the
40
41 342 analyses. This should not cause any problem, because the pollen seasons of different pollen types
42
43 343 commonly overlap, so individuals can react to exposure to several pollen types. Consequently, the
44
45 344 reaction to pollen exposure is likely to be a combined reaction to a sum of various pollen
46
47 345 types.[51] It is not always possible to define exactly which specific pollen type caused the
48
49 346 symptoms. Therefore, the exact separation of distinct pollen types in health effect studies is
50
51 347 somewhat artificial and thus, unnecessary.
52
53 348

54 349 **Synthesis with previous knowledge**

55 350 Our results indicated that short-term pollen exposure increases the risk of any respiratory or other
56
57 351 allergic symptom, lower and upper respiratory symptoms and ocular symptoms among allergic
58
59 352 and/or asthmatic subjects. Depending on the plant species, concentrations of pollen grains in the
60
353 breathing air can vary between zero and thousands. Eventually, increases in pollen exposure can
354 have a considerable effect on the well-being of allergic/asthmatic people. In a recent systematic

1
2
3 355 review and meta-analysis of 14 studies,[52] the mean number of emergency department
4
5 356 attendance among children and adolescents with asthma increased 1.88% (95% CI = 0.94%-2.82%)
6
7 357 in relation to a 10 grass pollen grain increase per cubic meter. These results are in line with a
8
9 358 recent ecologic study from Japan, where a positive association was observed between cedar and
10
11 359 cypress pollen counts and the prevalence of symptoms of allergic rhinoconjunctivitis and asthma
12
13 360 in school children.[53] Similarly, our results are also in line with the register-based time-series
14
15 361 analysis among Belgian population, where a positive association was observed between pollen
16
17 362 exposure and allergy medication sales.[54] A time-stratified case-crossover study showed a
18
19 363 positive association between tree and weed pollen exposure and emergency department visits
20
21 364 due to asthma exacerbations among 13-17 year- old U.S. asthmatics.[55]

22 365 According to our results, the effect of pollen exposure was stronger in upper respiratory tract
23
24 366 than in lower respiratory tract. This could be explained by the large size of the pollen grain.
25
26 367 Generally, the size of pollen varies between 20 and 100 micrometers in diameter.[56] Therefore,
27
28 368 particles of pollen grain size do not penetrate well into the lower respiratory tract.[57] Pollen
29
30 369 grains are likely to adhere and release their allergenic content already in the upper respiratory
31
32 370 tract. As a consequence of this, the majority of the direct allergic inflammatory effects caused by
33
34 371 pollen may be experienced in the region of the upper respiratory tract.

35 372 Our systematic review did not detect any major effect of pollen exposure on lung function. The
36
37 373 results may be explained by the fact that the study population for lung function effects included
38
39 374 healthy people in addition to allergic and asthmatic subjects. If these studies would only include
40
41 375 allergic and/or asthmatic persons, more pronounced effects might be detected. In the Swedish
42
43 376 cohort-based study, exposure to grass pollen during the preceding day was associated with a
44
45 377 reduced forced expiratory volume in relation to an increase in three pollen counts (/m³) among
46
47 378 the 8-year-old children.[58] This association was more pronounced among children who were
48
49 379 sensitized to pollen allergens. In line with those results, another study of Swedish adults showed
50
51 380 that pollen exposure resulted in significantly increased concentration of nitric oxide in exhaled air,
52
53 381 which suggested increased airway inflammation among these asthmatics compared to the healthy
54
55 382 controls.[59]

56 383

56 384 **Conclusions**

58 385 This systematic review and meta-analysis provides new evidence that short-term exposure to
59
60 386 pollen grains increases any respiratory symptoms, as well as specifically upper respiratory and

1
2
3 387 ocular symptoms among allergic and asthmatic subjects. It is important that clinicians take into
4
5 388 account, when working with allergic and asthmatic patients that even relatively short-term
6
7 389 exposure to pollen can induce for them symptoms of allergies and asthma. Clinicians should advice
8
9 390 allergic and asthmatic subjects to avoid spending much time outdoors during the (main) pollen
10
11 391 periods, and to use adequate allergy and asthma medications when such exposures cannot be
12
13 392 avoided. Future studies should use personal exposure assessment and it would be important to
14
15 393 find out how the variation in pollen exposure affects the health of allergic and asthmatic subjects.
16
17 394

18 395 **Acknowledgments**

19
20 396 We thank Riitta Aittamaa for her valuable assistance with figure editing. We also thank the
21
22 397 organizing committee of the 6th European Symposium on Aerobiology held in Lyon, France, July
23
24 398 2016 to possibility to present the main results of the study.
25
26 399

27 400 **Contributors**

28
29 401 JJ and TH conceived the study; MK, DRY and TH reviewed the articles, NS and MK analyzed the
30
31 402 data under supervision of JJ; MK, TH, MJ, and JJ wrote the manuscript, all authors contributed to
32
33 403 the intellectual content and approved the final version
34
35 404

36 405 **Data sharing statement**

37
38 406 Data are available upon reasonable request.
39
40 407
41

42 408 **Patient consent**

43
44 409 Not required
45
46 410
47

48 411 **Funding**

49
50 412 This work was supported by the Research Council for Health, the Academy of Finland [grant
51
52 413 numbers 266314, 267675, 267995 (APTA Consortium) and 24302585 (GLORIA Consortium)], and
53
54 414 the University of Oulu Strategic Funding. The funders had no role in study design, data collection
55
56 415 or analysis, decision to publish, or preparation of the manuscript.
57
58 416

59 417 **Competing Interests** None declared.
60

1
2
3 418
4
5 419
6
7 420
8
9 421
10
11 422
12
13 423
14 424
15
16 425
17
18 426
19
20 427
21
22 428
23 429
24
25 430
26
27 431
28
29 432
30
31 433
32
33 434
34 435
35 436
36
37 437
38
39 438
40
41 439
42 440
43
44 441
45
46 442
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends to the figures

Figure 1 Flow diagram showing searches and study selection.

Figure 2 Forest plot for the relation between pollen exposure and any symptom (Weights are from random effects analysis).

Figure 3 A Forest plot for the relation between pollen exposure and lower respiratory symptoms (Weights are from random effects analysis). **B.** Forest plot for the relation between pollen exposure and upper respiratory symptoms (Weights are from random effects analysis). **C.** Forest plot for the relation between pollen exposure and ocular symptoms (Weights are from random effects analysis). **D.** Forest plot for the relation between pollen exposure and symptom score (Weights are from random effects analysis).

Supplementary File, Figure 1 A. Forest plot for the relation between pollen exposure and peak expiratory flow (PEF; Weights are from random effects analysis). **B.** Forest plot for the relation between pollen exposure and forced expiratory volume (FEV; Weights are from fixed effects analysis).

Supplementary File, Figure 2 Funnel plot with pseudo 95% confidence limits for the relation between short-term pollen exposure and any symptom.

1
2
3 443 **REFERENCES**
4


- 5 444 1. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA
6 445 Dissemination Committee report. *Allergy*2004;59:469–478.
- 8 446 2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008
9 447 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).
11 448 *Allergy*2008;86:8–160.
- 13 449 3. Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. *Ther Adv Respir*
14 450 *Dis*2012;6:11–23.
- 16 451 4. Ait-Khaled N, Pearce N, Anderson HR, et al. ISAAC Phase Three Study Group. Global map of the
17 452 prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and
19 453 Allergies in Childhood (ISAAC) Phase Three. *Allergy*2009;64:123–148.
- 21 454 5. Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to
22 455 asthma control. *Eur Respir J*2015;46:622–639.
- 24 456 6. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. *Eur Respir*
25 457 *J*2004;24:758–764.
- 27 458 7. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-
29 459 sectional world health survey. *BMC Public Health*2012;12:204.
- 31 460 8. Nathan RA, Meltzer EO, Derebery J, et al. The prevalence of nasal symptoms attributed to
32 461 allergies in the United States: findings from the burden of rhinitis in an America survey. *Allergy*
33 462 *Asthma Proc*2008;29:600–608.
- 35 463 9. National Health Interview Survey (NHIS) Data; Most Recent Asthma Data. The Centers for
36 464 Disease Control and Prevention (CDC), 2016.
38 465 https://www.cdc.gov/asthma/most_recent_data.htm (accessed 25 September 2018).
- 40 466 10. Wang XY, Ma TT, Wang XY, et al. Prevalence of pollen-induced allergic rhinitis with high pollen
41 467 exposure in grasslands of northern China. *Allergy*2018;73(6):1232–1243.
- 43 468 11. Blomme K, Tomassen P, Lapeere H, et al. Prevalence of allergic sensitization versus allergic
44 469 rhinitis symptoms in an unselected population. *Int Arch Allergy Immunol*2013;160:200–207.
- 46 470 12. Darrow LA, Hess J, Rogers CA, et al. Ambient pollen concentrations and emergency department
47 471 visits for asthma and wheeze. *J Allergy Clin Immunol*2012;130(3):630–638.
- 49 472 13. Annesi-Maesano I, Rouve S, Desqueyroux H, et al. Grass pollen counts, air pollution levels and
50 473 allergic rhinitis severity. *Int Arch Allergy Immunol*2012;158:397–404.
- 53 474 14. Feo Brito F, Mur Gimeno P, Carnés J, et al. Grass pollen, aeroallergens, and clinical symptoms
54 475 in Ciudad Real, Spain. *J Investig Allergol Clin Immunol*2010;20(4):295–302.
- 56 476 15. DellaValle CT, Triche EW, Leaderer BP, et al. Effects of Ambient Pollen Concentrations on
57 477 Frequency and Severity of Asthma Symptoms among Asthmatic Children. *Epidemiology*2012;
59 478 23(1):55–63.
60


- 1
2
3 479 16. Taylor PE, Jacobson KW, House JM, et al. Links between pollen, atopy and the asthma
4 480 epidemic. *Int Arch Allergy Immunol*2007;144:162–170.
- 6 481 17. Caillaud D, Thibaudon M, Martin S, et al. Short-term effects of airborne ragweed pollen on
7 482 clinical symptoms of hay fever in a panel of 30 patients. *J Investig Allergol Clin
9 483 Immunol*2014a;24(4):249–256.
- 11 484 18. Häfner D, Reich K, Matricardi PM, et al. Prospective validation of ‘Allergy-Control-SCORE™’: a
12 485 novel symptom–medication score for clinical trials. *Allergy*2011;66:629–636.
- 14 486 19. Roberts G, Mylonopoulou M, Hurley C, et al. Impairment in quality of life is directly related
15 487 to the level of allergen exposure and allergic airway inflammation. *Clin Exp Allergy*2005;35:1295–
17 488 1300.
- 19 489 20. Delfino RJ, Zeiger RS, Seltzer JM, et al. Association of asthma symptoms with peak particulate
20 490 air pollution and effect modification by anti-inflammatory medication use. *Environ Health
21 491 Perspect*2002;110(10):A607–A617.
- 23 492 21. Ostro B, Lipsett M, Mann J, et al. Air pollution and exacerbation of asthma in African-American
24 493 children in Los Angeles. *Epidemiology*2001;12:200–208.
- 26 494 22. Baraldi E, Carrà S, Dario C, et al. Effect of natural grass pollen exposure on exhaled nitric oxide
27 495 in asthmatic children. *Am J Respir Crit Care Med*1999;159:262–266.
- 30 496 23. Delfino RJ, Zeiger RS, Seltzer JM, et al. The effect of outdoor fungal spore concentrations on
31 497 daily asthma severity. *Environ Health Perspect*1997;105(6):622–635.
- 33 498 24. Ross MA, Persky VW, Scheff PA, et al. Effect of ozone and aeroallergens on the respiratory
34 499 health of asthmatics. *Arch Environ Health*2002;57(6):568–578.
- 36 500 25. Scarlett JF, Abbott KJ, Peacock JL, et al. Acute effects of summer air pollution on respiratory
37 501 function in primary school children in southern England. *Thorax*1996;51:1109–1114.
- 39 502 26. Studnicka MJ, Frischer T, Meinert R, et al. Acidic particles and lung function in children: a
40 503 summer camp study in the Austrian Alps. *Am J Respir Crit Care Med*1995;151:423–430.
- 43 504 27. Roberts G, Hurley C, Bush A, et al. Longitudinal study of grass pollen exposure, symptoms, and
44 505 exhaled nitric oxide in childhood seasonal allergic asthma. *Thorax*2004;59:752–756.
- 46 506 28. Caillaud D, Toloba Y, Raobison R, et al. Health impact of exposure to pollens: A review of
47 507 epidemiological studies. [Article in French]. *Rev Mal Respir*2014b;31(2):142–149.
- 49 508 29. Newhouse CP, Levetin E. Correlation of environmental factors with asthma and rhinitis
50 509 symptoms in Tulsa OK. *Ann Allergy Asthma Immunol*2004;92:356–366.
- 53 510 30. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. 2009. Preferred Reporting
54 511 Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS
55 512 Med*6(7):e1000097.
- 57 513 31. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias.
58 514 *Biometrics*1994;50(4):1088–1101.
- 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


32. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ*1997;315(7109):629–634.
33. Caillaud DM, Martin S, Segala C, et al. Nonlinear short-term effects of airborne Poaceae levels on hay fever symptoms. *J Allergy Clin Immunol*2012;130(3):812–814.
34. Caillaud D, Martin S, Segala C, et al. Effects of airborne birch pollen levels on clinical symptoms of seasonal allergic rhinoconjunctivitis. *Int Arch Allergy Immunol*2014c;163:43–50.
35. Delfino RJ, Coate BD, Zeiger RS, et al. Daily asthma severity in relation to personal ozone exposure and outdoor fungal spores. *Am J Respir Crit Care Med*1996;154:633–641.
36. Djukanović R, Feather I, Gratiou C, et al. Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. *Thorax*1996;51(6):575–581.
37. Domínguez-Vilches E, Cariñanos P, Galán Soldevilla C, et al. Airborne pollen concentrations, solid particle content in the air and allergy symptoms in Córdoba (Spain). *Aerobiologia*1995;11(2):129–135.
38. Feo Brito F, Mur Gimeno P, Martínez C, et al. Air pollution and seasonal asthma during the pollen season. A cohort study in Puertollano and Ciudad Real (Spain). *Allergy*2007;62(10):1152–1157.
39. Feo Brito F, Mur Gimeno P, Carnés J, et al. Olea europaea pollen counts and aeroallergen levels predict clinical symptoms in patients allergic to olive pollen. *Ann Allergy Asthma Immunol*2011;106(2):146–152.
40. Grammer L, Wiggins C, Shaughnessy MA, et al. Absence of nasal priming as measured by rhinitis symptom scores of ragweed allergic patients during seasonal exposure to ragweed pollen. *Allergy Proc*1990;11(5):243–246.
41. Jantunen J, Saarinen K, Rantio-Lehtimäki A. Allergy symptoms in relation to alder and birch pollen concentrations in Finland. *Aerobiologia*2012;28:169–176.
42. Klabuschnigg A, Götz M, Horak F, et al. Influence of aerobiology and weather on symptoms in children with asthma. *Respiration*1981;42(1):52–60.
43. Krämer U, Weidinger S, Darsow U, et al. Seasonality in symptom severity influenced by temperature or grass pollen: results of a panel study in children with eczema. *J Invest Dermatol*2005;124:514–523.
44. Petersen BN, Sandberg I. Diagnostics in allergic diseases by correlating pollen/fungal spore counts with patient scores of symptoms. *Grana*1981;20:219–224.
45. Schäppi GF, Taylor PE, Kenrick J, et al. Predicting the grass pollen count from meteorological data with regard to estimating the severity of hayfever symptoms in Melbourne (Australia). *Aerobiologia*1998;14:29–37.
46. Taudorf E, Moseholm L. Pollen count, symptom and medicine score in birch pollinosis. A mathematical approach. *Int Arch Allergy Appl Immunol*1988;86:225–233.

- 1
2
3 551 47. Riediker M, Keller S, Wüthrich B, et al. Personal pollen exposure compared to stationary
4 552 measurements. *J Investig Allergol Clin Immunol*2000;10(4):200–203.
- 6 553 48. Hugg TT, Hjort J, Antikainen H, et al. Urbanity as a determinant of exposure to grass pollen in
8 554 Helsinki Metropolitan area, Finland. *PLOS ONE*2017;12(10):e0186348.
- 10 555 49. Osborne NJ, Alcock I, Wheeler BW, et al. Pollen exposure and hospitalization due to asthma
11 556 exacerbations: daily time series in a European city. *Int J Biometeorol*2017;61(10):1837–1848.
- 13 557 50. Robertson DG, Kerigan AT, Hargreave FE, et al. Late asthmatic responses induced by ragweed
14 558 pollen allergen. *J Allergy Clin Immunol*1974;54(4):244–254.
- 16 559 51. D'Amato G, Cecchi L, Bonini S, et al. Allergenic pollen and pollen allergy in Europe.
17 560 *Allergy*2007;62(9):976–990.
- 19 561 52. Erbas B, Jazayeri M, Lambert KA, et al. Outdoor pollen is a trigger of child and adolescent
21 562 asthma emergency department presentations: A systematic review and meta-analysis.
22 563 *Allergy*2018;73(8):1632–1641.
- 24 564 53. Yoshida K, Adachi Y, Akashi M, et al. Cedar and cypress pollen counts are associated with the
25 565 prevalence of allergic diseases in Japanese schoolchildren. *Allergy*2013;68(6):757–763.
- 27 566 54. Guilbert A, Simons K, Hoebeke L, et al. Short-term effect of pollen and spore exposure on
29 567 allergy morbidity in the Brussels-Capital region. *Ecohealth*2016; 13(2):303–315.
- 31 568 55. Gleason JA, Bielory L, Fagliano JA. Associations between ozone, PM2.5, and four pollen types
32 569 on emergency department pediatric asthma events during the warm season in New Jersey: a case-
33 570 crossover study. *Environ Res*2014;132:421–429.
- 35 571 56. Haahtela T, Sorsa P. Kasviallergiat ja allergiakasvit [Plant allergies and allergenic plants; in
37 572 Finnish]. Helsinki: *Kirjayhtymä* 1999.
- 39 573 57. Suphioglu C, Singh MB, Taylor P, et al. Mechanism of grass-pollen-induced asthma.
40 574 *Lancet*1992;339(8793):569–572.
- 42 575 58. Gruzieva O, Pershagen G, Wickman M, et al. Exposure to grass pollen--but not birch pollen--
43 576 affects lung function in Swedish children. *Allergy*2015;70(9):1181–1183.
- 45 577 59. Bake B, Viklund E, Olin AC. Effects of pollen season on central and peripheral nitric oxide
46 578 production in subjects with pollen asthma. *Respir Med*2014;108(9):1277–1283.
- 48
49 579
50
51
52
53
54
55
56
57
58
59
60







A Lower respiratory symptoms




B Upper respiratory symptoms



C Ocular symptoms



D Symptom score



Supplementary File, Table 1. List of search terms and related combinations used in PubMed database search.

First phase	Second phase
Panel study AND Pollen	Pollen (Mesh) AND Cohort studies (Mesh)
	Pollen (Mesh) AND Longitudinal studies (Mesh)
	Pollen (Mesh) AND Follow-up studies (Mesh)
	Pollen (Mesh) AND Case-control studies (Mesh)
	Pollen (Mesh) AND Cross-sectional studies (Mesh)
	Pollen (Mesh) AND Cohort studies (Mesh) AND Asthma (Mesh)
	Pollen (Mesh) AND Longitudinal studies (Mesh) AND Asthma (Mesh)
	Pollen (Mesh) AND Follow-up studies (Mesh) AND Asthma (Mesh)
	Pollen (Mesh) AND Case-control studies (Mesh) AND Asthma (Mesh)
	Pollen (Mesh) AND Cross-sectional studies (Mesh) AND Asthma (Mesh)

Supplementary Table 2. Risk of bias tables.

Caillaud et al. 2012		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 71.1%; "43 volunteers were excluded, either because they failed to provide the requested daily health records (n=24) or because they did not fulfill the inclusion criteria (n=19)"
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

Caillaud et al. 2014a		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 96.8%; "One participant was excluded because he failed to provide the requested daily health records during the month of August and additionally he experienced hay fever before the pollen season."
Selective reporting (reporting bias)	Low risk	Protocol was not available but it was clear that all pre-specified and expected outcomes of interest were reported
Other bias	Low risk	There was some overlap among the study subjects, so that seven individuals (23% of participants) were included study groups in both years. "Of these 31 patients, 7 participated in the 2 years." Positively sensitized patients were involved.

		“It would have been preferable to include patients who were strictly monosensitized to <i>A. artemisiifolia</i> in order to obtain more accurate results regarding the relationship between pollen exposure and symptoms [31]. However, due to the rarity of monosensitized patients, the study had to include polysensitized patients.”
Caillaud et al. 2014c		
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 85.9%; “Ten participants were excluded either because they failed to provide the requested daily health records (n=8) or because they did not qualify for inclusion (N=2).” Partly missing symptom data. “Missing symptom score data occurred on 285 person-days (8.6% of the total expected follow-up of 3,311 person-days) because subjects had left the study area all day...”
Selective reporting (reporting bias)	Low risk	Protocol was not available but it was clear that all pre-specified and expected outcomes of interest were reported
Other bias	Low risk	None were identified

Delfino et al. 2002		
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design

Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 88.0%. "A 10-year-old boy and a 14-year-old girl dropped out after the second week of study and are not retained for analysis. One white 10-year-old male was asymptomatic throughout the panel period and therefore contributed no information to the repeated-measures analysis." Partly missing symptom data. "Missing symptom score data occurred on 51 person-days (3.8% of total expected follow-up of 1,328 person-days) because subjects had left the study area all day, and on 29 person-days because of noncompliance with diary completion (2.2%), ..."
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

Della Valle et al. 2012		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 92.3%; "We restricted the analysis to 630 subjects who completed an exit interview and who lived primarily within the northeastern U.S. throughout follow-up, ..."
Selective reporting (reporting bias)	Low risk	Protocol was not available but it was clear that all pre-specified and expected outcomes of interest were reported.
Other bias	Low risk	None were identified

Feo Brito et al. 2007		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 90.1%. "... seven patients withdrew in Puertollano and eight patients in Ciudad Real leaving a final study population of 137 patients ..."
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

Feo Brito et al. 2011		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 100%
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

Ostro et al. 2001		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design

Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 90.2%; "Five subjects who provided baseline data never provided any daily diary information. In addition, data from 10 subjects (representing 8.3% of the person-days) were excluded from the analysis because of evidence that the intake data or diary data were likely to have been inaccurate, or because the diaries were returned more than 2 weeks late." Partly feasible symptom data. "A total of 10,022 person-days of symptom data were reported, of which we used 9,126 in the analysis after the health data of questionable validity were excluded."
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

Roberts et al. 2005		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 100%
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

Ross et al. 2002		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 67.8%. "Two families withdrew early in the study period, and a number of participants either withdrew later in the study or failed to provide the requested daily health records ... The 2 primary reasons stated for withdrawal from the study were a lack of time or interest in participating, or a move from the study area. Partly missing symptom data. "The last few days of data were excluded because of the small number of remaining participants."
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified



Scarlett et al. 1996		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk to high risk	Follow-up rate was 100%
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	High risk	Not feasible asthma medication data. "Children on medication for asthma were asked whether they had taken any medication that day. Unfortunately, the quality of these data were


		poor and so they were not used in the analysis. At worst this would bias the regression coefficients towards the null value.”
--	--	---

Studnicka et al. 1995		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Not applicable	Epidemiologic study design
Allocation concealment (selection bias)	Not applicable	Epidemiologic study design
Blinding (performance bias and detection bias)	Not applicable	Epidemiologic study design
Incomplete outcome data (attrition bias)	Low risk	Follow-up rate was 88.7%; “For three, five, and seven children, respectively, permission was denied (for the 1st, 2nd, and 3rd panel). For Panel 3, two children were not able to perform reproducible spirometry.”
Selective reporting (reporting bias)	Unclear	Not enough information to make a clear judgement
Other bias	Low risk	None were identified

bmjopen-2019-029669 on 10 January 2020. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46







PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	2
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	4
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	9, FIG1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	9
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	study protocol
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	14
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	9



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	14
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	N/A
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICCO, follow-up period) and provide the citations.	Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Table 1
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	FIG2-FIG3, Suppl Fig1
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	FIG2-FIG3, Suppl Fig1
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	14
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	14-16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16-17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	18



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only

136/bmjopen-2019-029009 on 10 January 2020. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.